Common use of BASIS FOR THE PREPARATION OF FINANCIAL STATEMENTS Clause in Contracts

BASIS FOR THE PREPARATION OF FINANCIAL STATEMENTS. 2.1 Basis for preparation of the interim financial statements These interim financial statements are prepared in accordance with Thai Accounting Standard No. 34 Interim Financial Reporting, and the requirements of the Securities and Exchange Commission (SEC). The interim financial statements are intended to provide information additional to that included in the latest annual financial statements. Accordingly, they focus on new activities, events, and situations and not intended to re-emphasis on the information previously reported. The interim financial statements should therefore, be read in conjunction with the financial statements for the year ended December 31, 2020. The interim financial statements have been prepared on a historical cost basis except where otherwise disclosed in the accounting policies. The interim financial statements in Thai language are the official statutory financial statements of the Company. The interim financial statements in English language have been translated from the financial statements in Thai language version. 2.2 Basis for the preparation of consolidated financial statements 2.2.1 The consolidated financial statements have included the financial statements of Vibhavadi Medical Center Public Co., Ltd., subsidiaries and associated companies as follows; Percentage of holding % of share capital Name of Company Type of business As at March 31, 2021 As at December 31, 2020 Head office location Chiang Mai Ram Medical Business Public Co., Ltd. Hospital 83.55 83.55 Chiang Mai Beauty Design Center Co., Ltd. Beauty Business 50.00 50.00 Bangkok V.precision Co., Ltd. Anti Aging Center 70.00 70.00 Bangkok Percentage of holding % of share capital Name of Company Type of business As at March 31, 2021 As at December 31, 2020 Head office location Vibharam Hospital Co., Ltd. Hospital 33.73 33.73 Bangkok Thippayabadin Co., Ltd. Trading medical 38.18 38.18 Bangkok instruments Bangpo General Hospital Co., Ltd. Hospital 28.57 28.57 Bangkok Chiang Mai Ram Hospital Co., Ltd. Hospital 47.09 47.09 Chiang Mai Hariphunchai Memorial Co., Ltd. Hospital 72.43 72.43 Lamphun Theppanya Business Co., Ltd. Hospital 47.09 47.09 Chiang Mai Ramkhamhaeng Chiangmai Hospital Co., Ltd. Hospital 45.14 45.14 Chiang Mai Khelang Nakorn Hospital Co., Ltd. Hospital 11.99 11.99 Lampang Pawo Hospital Co., Ltd. Hospital 23.54 23.54 Tak 2.2.2 Accounting policy for subsidiary companies will utilize the same policy as Vibhavadi Medical Center Public Company Limited. 2.2.3 Outstanding balances and significant transactions between the Company and its subsidiaries have been eliminated from the consolidated financial statements. 2.2.4 Non-controlling interests represent the portion of profit or loss and net assets of the subsidiaries that are not held by the Company and are presented separately from the portion of owners of the parent. 2.3 Financial reporting standards that became effective in the current period During the period, the Company and its subsidiaries have adopted the revised financial reporting standards and interpretations which are effective for fiscal years beginning on or after January 1, 2021. These financial reporting standards were aimed at alignment with the corresponding International Financial Reporting Standards with most of the changes directed towards clarifying accounting treatment and providing accounting guidance for users of the standards. The adoption of these financial reporting standards does not have any significant impact on the financial statements in the current period. 2.4 Financial reporting standards that will become effective in the future The Federation of Accounting Professions has revised TFRS 16 lease agreements and published in the Government Gazette on January 27, 2021. There is added the requirements for the temporary exception arising from interest rate benchmark reform, which an entity shall apply these amendments for annual reporting periods beginning on or after January 1, 2022 with earlier application permitted. The management of the Company and its subsidiaries are currently evaluating the impact of these standards to the financial statements in the year when they are adopted. 2.5 Cumulative effect from the previous period's financial statements before classification and other financial asset value In 2020, the Company set an investment objective in the financial assets type investment in marketable equity with the nature held for sale as current financial assets. As a result, the Company has to reclassify and remeasure other financial assets by restating the financial statements for classification and measurement of such items into profit or loss to follow the objectives of the company. Therefore, the Company has restated the financial statements presented for comparative purposes and presented the consolidated statement of financial position and separate statement of financial position as at January 1, 2020 for comparative information as if the Company had correctly recorded the accounts. The cumulative effect of such adjustment is presented as a separate item in the statement of changes in shareholder's equity. The amounts of adjustments that have effect on the items in the statement of financial position and statement of comprehensive income are as follows: • Statements of financial position Consolidated financial statements As at December 31, 2020 As at January 1, 2020 As previously reported Adjustment increase (decrease) As restated As previously reported Adjustment increase (decrease) As restated Asset Other current financial asset - 156,910,000 156,910,000 - 56,102,150 56,102,150 Other non-current financial asset 7,900,167,417 (156,910,000) 7,743,257,417 7,360,434,110 (56,102,150) 7,304,331,960 Retained earnings - unappropriated 2,449,130,766 11,749,897 2,460,880,663 2,583,221,873 (3,923,281) 2,579,298,592 Other components of shareholders' equity 1,496,407,944 (11,749,897) 1,484,658,047 1,377,393,221 3,923,281 1,381,316,502 Separate financial statements As at December 31, 2020 As at January 1, 2020 As previously reported Adjustment increase (decrease) As restated As previously reported Adjustment increase (decrease) As restated Asset Other current financial asset - 156,910,000 156,910,000 - 56,102,150 56,102,150 Other non-current financial asset 5,145,443,263 (156,910,000) 4,988,533,263 4,401,296,413 (56,102,150) 4,345,194,263 Retained earnings - unappropriated 980,203,060 11,749,897 991,952,957 1,022,620,856 (3,923,281) 1,018,697,575 Other components of shareholders' equity 738,042,960 (11,749,897) 726,293,063 490,009,847 3,923,281 493,933,128 • Statements of comprehensive income For the three-month periods ended March 31, 2020 Consolidated financial statements Separate financial statements As previously reported Adjustment increase (decrease) As restated As previously reported Adjustment increase (decrease) As restated Loss on fair value measurement of financial assets - (19,501,231) (19,501,231) - (19,501,231) (19,501,231) Profit from operating activities 275,004,361 (19,501,231) 255,503,130 353,967,286 (19,501,231) 334,466,055 Profit before income tax expenses 250,224,650 (19,501,231) 230,723,419 323,799,701 (19,501,231) 304,298,470 Income tax expenses 37,533,625 (3,900,246) 33,633,379 8,716,132 (3,900,246) 4,815,886 Profit for the period 212,691,025 (15,600,985) 197,090,040 315,083,569 (15,600,985) 299,482,584 Loss on investment in equity designated at fair value through other comprehensive income (654,867,821) 19,501,231 (635,366,590) (448,215,238) 19,501,231 (428,714,007) Income tax relating to items that will not be reclassified 130,973,564 (3,900,246) 127,073,318 89,643,047 (3,900,246) 85,742,801 Other comprehensive income (loss) for the period, net of income tax (572,096,680) 15,600,985 (556,495,695) (358,572,191) 15,600,985 (342,971,206) Profit attributable - Owners of the parent 151,048,058 (15,600,985) 135,447,073 315,083,569 (15,600,985) 299,482,584 Basic earnings per share 0.0114 (0.0012) 0.0102 0.0238 (0.0012) 0.0226 Diluted earnings per share 0.0103 (0.0011) 0.0092 0.0214 (0.0010) 0.0204

BASIS FOR THE PREPARATION OF FINANCIAL STATEMENTS. 2.1 Basis for preparation of the interim financial statements These interim The financial statements are have been prepared in accordance with the accounting standards prescribed by Thai Accounts Act enunciated under the Accounting Standard No. 34 Interim Financial Reporting, and the requirements of the Securities and Exchange Commission (SEC). The interim financial statements are intended to provide information additional to that included in the latest annual financial statements. Accordingly, they focus on new activities, events, and situations and not intended to re-emphasis on the information previously reported. The interim financial statements should therefore, be read in conjunction Profession Act B.E.2547 by complying with the financial statements for the year ended December 31, 2020reporting standards. The interim presentation of the financial statements has been made in compliance with the Notification of the Department of Business Development, the Ministry of Commerce, re : the financial statements presentation for public limited company, issued under the Accounting Act B.E. 2543. The financial statements have been prepared on a historical cost basis except where otherwise disclosed in the accounting policies. The interim financial statements in Thai language are the official statutory financial statements of the Company. The interim financial statements in English language have been translated from the such financial statements in Thai language versionlanguage. 2.2 Basis for the preparation of consolidated financial statements 2.2.1 The consolidated financial statements have included the financial statements of Vibhavadi Medical Center Public Co., Ltd., subsidiaries and associated companies as follows; Type of Percentage of holding % of share capital Name of Company Type of business As at March 31, 2021 As at December 31, 2020 Head office location Chiang Mai Ram Medical Business Public Co., Ltd. Associated company Hospital 83.55 83.55 Chiang Mai Beauty Design Center Co., Ltd. Beauty Business 50.00 50.00 Bangkok V.precision Co., Ltd. Anti Aging Center 70.00 70.00 Bangkok Percentage of holding % of share capital Name of Company Type of business As at March 31, 2021 As at December 31, 2020 Head office location Vibharam Hospital Co., Ltd. Hospital 33.73 33.73 40.75 40.75 Bangkok Thippayabadin Co., Ltd. Trading medical 38.18 38.18 33.33 50.00 Bangkok instruments Bangpo General Hospital Co., Ltd. Hospital 28.57 28.57 Bangkok Type of Percentage of holding % of share capital Head office Chiang Mai Ram Hospital Co., Ltd. Hospital 47.09 47.09 Chiang Mai Hariphunchai Memorial Co., Ltd. Hospital 72.43 72.43 Lamphun Beauty Design Center Co., Ltd. Beauty Business 50.00 50.00 Bangkok Theppanya Business Co., Ltd. Hospital 47.09 47.09 Chiang Mai Ramkhamhaeng Chiangmai Hospital Co., Ltd. Hospital 45.14 45.14 Chiang Mai Khelang Nakorn Hospital Co., Ltd. Hospital 11.99 11.99 Lampang Pawo Hospital Co., Ltd. Hospital 23.54 23.54 Tak 2.2.2 Accounting policy for subsidiary companies will utilize the same policy as Vibhavadi Medical Center Public Company Limited. 2.2.3 Outstanding balances and significant transactions between the Company and its subsidiaries have been eliminated from the consolidated financial statements. 2.2.4 Non-controlling interests represent the portion of profit or loss and net assets of the subsidiaries that are not held by the Company and are presented separately from the portion of owners of the parent. 2.3 Financial The financial reporting standards that became are effective in the current period During the period, the Company and its subsidiaries have adopted year The Federation of Accounting Professions (FAP) has issued Notifications to mandate the revised accounting standards, financial reporting standards standards, and interpretations of accounting and financial reporting standards, which are effective for the fiscal years year beginning on or after January 1, 2021. These 2018 are as follows: TAS 1 (revised 2017) Presentation of Financial Statements TAS 2 (revised 2017) Inventories TAS 7 (revised 2017) Statement of Cash Flows TAS 8 (revised 2017) Accounting Policies, Changes in Accounting Estimates and Errors TAS 10 (revised 2017) Events After the Reporting Period TAS 11 (revised 2017) Construction Contracts TAS 12 (revised 2017) Income Taxes TAS 16 (revised 2017) Property, Plant and Equipment TAS 17 (revised 2017) Leases TAS 18 (revised 2017) Revenue TAS 19 (revised 2017) Employee Benefits TAS 20 (revised 2017) Accounting for Government Grants and Disclosure of Government Assistance TAS 21 (revised 2017) The Effects of Changes in Foreign Exchange Rates TAS 23 (revised 2017) Borrowing Costs TAS 24 (revised 2017) Related Party Disclosures TAS 26 (revised 2017) Accounting and Reporting by Retirement Benefit Plans TAS 27 (revised 2017) Separate Financial Statements TAS 28 (revised 2017) Investments in Associates and Joint Ventures TAS 29 (revised 2017) Financial Reporting in Hyperinflationary Economies TAS 33 (revised 2017) Earnings Per Share TAS 34 (revised 2017) Interim Financial Reporting TAS 36 (revised 2017) Impairment of Assets TAS 37 (revised 2017) Provisions, Contingent Liabilities and Contingent Assets TAS 38 (revised 2017) Intangible assets TAS 40 (revised 2017) Investment Property TAS 41 (revised 2017) Agriculture TFRS 2 (revised 2017) Share-Based Payment TFRS 3 (revised 2017) Business Combinations TFRS 4 (revised 2017) Insurance Contracts TFRS 5 (revised 2017) Non-current Assets Held for Sale and Discontinued Operations TFRS 6 (revised 2017) Exploration for and Evaluation of Mineral Resource TFRS 8 (revised 2017) Operating Segments TFRS 10 (revised 2017) Consolidated Financial Statements TFRS 11 (revised 2017) Joint Arrangements TFRS 12 (revised 2017) Disclosure of Interests in Other Entities TFRS 13 (revised 2017) Fair Value Measurement TSIC 10 (revised 2017) Government Assistance - No Specific Relation to Operating Activities TSIC 15 (revised 2017) Operating Leases - Incentives TSIC 25 (revised 2017) Income Taxes - Changes in the Tax Status of an Entity or its Shareholders TSIC 27 (revised 2017) Evaluating the Substance of Transactions Involving the Legal Form of a Lease TSIC 29 (revised 2017) Service Concession Arrangements: Disclosure TSIC 31 (revised 2017) Revenue-Barter Transactions Involving Advertising Services TSIC 32 (revised 2017) Intangible Assets - Web Site Costs TFRIC 1 (revised 2017) Changes in Existing Decommissioning, Restoration and Similar Liabilities TFRIC 4 (revised 2017) Determining whether an Arrangement contains a Lease TFRIC 5 (revised 2017) Right to Interests arising from Decommissioning, Restoration and Environmental Rehabilitation Funds TFRIC 7 (revised 2017) Applying the Restatement Approach under TAS 29 (revised 2017) Financial Reporting in Hyperinflationary Economics TFRIC 10 (revised 2017) Interim Financial Reporting and Impairment TFRIC 12 (revised 2017) Service Concession Arrangements TFRIC 13 (revised 2017) Customer Loyalty Programmes TFRIC 14 (revised 2017) TAS 19 (revised 2017)-The Limit on a Defined Benefit Asset, Minimum Funding Requirements and their Interaction TFRIC 15 (revised 2017) Agreements for the Construction of Real Estate TFRIC 17 (revised 2017) Distributions of Non - cash Assets to Owners TFRIC 18 (revised 2017) Transfers of Assets from Customers TFRIC 20 (revised 2017) Stripping Costs in the Production Phase of a Surface Mine TFRIC 21 (revised 2017) Levies The management of the Company and its subsidiaries evaluated that these revised accounting standards, financial reporting standard, accounting standard interpretations and financial reporting standards were aimed at alignment with the corresponding International Financial Reporting Standards with most of the changes directed towards clarifying accounting treatment and providing accounting guidance for users of the standards. The adoption of these financial reporting standards does interpretations do not have any significant impact on the financial statements in the current periodyear. 2.4 Financial reporting standards that will become effective in the future The Federation of Accounting Professions has revised TFRS 16 lease agreements and published in the Government Gazette on January 27, 2021. There is added the requirements for the temporary exception arising from interest rate benchmark reform, which an entity shall apply these amendments for annual reporting periods beginning on or after January 1, 2022 with earlier application permitted. The management of the Company and its subsidiaries are currently evaluating the impact of these standards to the financial statements in the year when they are adopted. 2.5 Cumulative effect from the previous period's financial statements before classification and other financial asset value In 2020, the Company set an investment objective in the financial assets type investment in marketable equity with the nature held for sale as current financial assets. As a result, the Company has to reclassify and remeasure other financial assets by restating the financial statements for classification and measurement of such items into profit or loss to follow the objectives of the company. Therefore, the Company has restated the financial statements presented for comparative purposes and presented the consolidated statement of financial position and separate statement of financial position as at January 1, 2020 for comparative information as if the Company had correctly recorded the accounts. The cumulative effect of such adjustment is presented as a separate item in the statement of changes in shareholder's equity. The amounts of adjustments that have effect on the items in the statement of financial position and statement of comprehensive income are as follows: • Statements of financial position Consolidated financial statements As at December 31, 2020 As at January 1, 2020 As previously reported Adjustment increase (decrease) As restated As previously reported Adjustment increase (decrease) As restated Asset Other current financial asset - 156,910,000 156,910,000 - 56,102,150 56,102,150 Other non-current financial asset 7,900,167,417 (156,910,000) 7,743,257,417 7,360,434,110 (56,102,150) 7,304,331,960 Retained earnings - unappropriated 2,449,130,766 11,749,897 2,460,880,663 2,583,221,873 (3,923,281) 2,579,298,592 Other components of shareholders' equity 1,496,407,944 (11,749,897) 1,484,658,047 1,377,393,221 3,923,281 1,381,316,502 Separate financial statements As at December 31, 2020 As at January 1, 2020 As previously reported Adjustment increase (decrease) As restated As previously reported Adjustment increase (decrease) As restated Asset Other current financial asset - 156,910,000 156,910,000 - 56,102,150 56,102,150 Other non-current financial asset 5,145,443,263 (156,910,000) 4,988,533,263 4,401,296,413 (56,102,150) 4,345,194,263 Retained earnings - unappropriated 980,203,060 11,749,897 991,952,957 1,022,620,856 (3,923,281) 1,018,697,575 Other components of shareholders' equity 738,042,960 (11,749,897) 726,293,063 490,009,847 3,923,281 493,933,128 • Statements of comprehensive income For the three-month periods ended March 31, 2020 Consolidated financial statements Separate financial statements As previously reported Adjustment increase (decrease) As restated As previously reported Adjustment increase (decrease) As restated Loss on fair value measurement of financial assets - (19,501,231) (19,501,231) - (19,501,231) (19,501,231) Profit from operating activities 275,004,361 (19,501,231) 255,503,130 353,967,286 (19,501,231) 334,466,055 Profit before income tax expenses 250,224,650 (19,501,231) 230,723,419 323,799,701 (19,501,231) 304,298,470 Income tax expenses 37,533,625 (3,900,246) 33,633,379 8,716,132 (3,900,246) 4,815,886 Profit for the period 212,691,025 (15,600,985) 197,090,040 315,083,569 (15,600,985) 299,482,584 Loss on investment in equity designated at fair value through other comprehensive income (654,867,821) 19,501,231 (635,366,590) (448,215,238) 19,501,231 (428,714,007) Income tax relating to items that will not be reclassified 130,973,564 (3,900,246) 127,073,318 89,643,047 (3,900,246) 85,742,801 Other comprehensive income (loss) for the period, net of income tax (572,096,680) 15,600,985 (556,495,695) (358,572,191) 15,600,985 (342,971,206) Profit attributable - Owners of the parent 151,048,058 (15,600,985) 135,447,073 315,083,569 (15,600,985) 299,482,584 Basic earnings per share 0.0114 (0.0012) 0.0102 0.0238 (0.0012) 0.0226 Diluted earnings per share 0.0103 (0.0011) 0.0092 0.0214 (0.0010) 0.0204

BASIS FOR THE PREPARATION OF FINANCIAL STATEMENTS. 2.1 Basis for preparation of the interim financial statements These interim The financial statements are have been prepared in accordance with the accounting standards prescribed by Thai Accounts Act enunciated under the Accounting Standard No. 34 Interim Profession Act B.E.2547 by complying with Thai Financial Reporting, and the requirements of the Securities and Exchange Commission (SEC)Reporting Standards. The interim financial statements are intended to provide information additional to that included in the latest annual financial statements. Accordingly, they focus on new activities, events, and situations and not intended to re-emphasis on the information previously reported. The interim financial statements should therefore, be read in conjunction with presentation of the financial statements has been made in compliance with the Notification of the Department of Business Development, the Ministry of Commerce, re : the financial statements presentation for public limited company, issued under the year ended December 31, 2020Accounting Act B.E. 2543. The interim financial statements have been prepared on a historical cost basis except where otherwise disclosed in the accounting policies. The interim financial statements in Thai language are the official statutory financial statements of the Company. The interim financial statements in English language have been translated from the such financial statements in Thai language versionlanguage. 2.2 Basis for the preparation of consolidated financial statements 2.2.1 The consolidated financial statements have included the financial statements of Vibhavadi Medical Center Public Co., Ltd., Ltd. subsidiaries and associated companies as follows; Type of Percentage of holding % of share capital Name of Company Type of business As at March 31, 2021 As at December 31, 2020 Head office location Chiang Mai Ram Medical Business Public Co., Ltd. Hospital 83.55 83.55 Chiang Mai Beauty Design Center Co., Ltd. Beauty Business 50.00 49.72 50.00 Bangkok V.precision V precision Co., Ltd. Anti Aging Center 70.00 70.00 Bangkok Type of Percentage of holding % of share capital Name of Company Type of business As at March 31, 2021 As at December 31, 2020 Head office location Vibharam Hospital Co., Ltd. Hospital 33.73 33.73 33.85 33.85 Bangkok Thippayabadin Co., Ltd. Trading medical 38.18 38.18 36.50 40.57 Bangkok instruments Bangpo General Hospital Co., Ltd. Hospital 28.57 28.57 Bangkok Indirect subsidiary and associated companies Subsidiary company Chiang Mai Ram Hospital Co., Ltd. Hospital 47.09 47.09 Chiang Mai Hariphunchai Memorial Co., Ltd. Hospital 72.43 72.43 Lamphun Theppanya Business Co., Ltd. Hospital 47.09 47.09 Chiang Mai Ramkhamhaeng Chiangmai Hospital Co., Ltd. Hospital 45.14 45.14 45.53 45.53 Chiang Mai (and held by Chiang Mai Ram Medical Business Public Co., Ltd. 18%) Pawo Hospital Co., Ltd. (1) Hospital 28.00 - Tak held by V precision Co., Ltd. Medica Bangkok Clinic Co., Ltd. (2) (and held by Beauty Design Center Co., Ltd. 30.00%) Specialized Disease Clinic 36.00 - Bangkok Khelang Nakorn Hospital Co., Ltd. Hospital 11.99 11.99 Lampang Pawo Hospital Co., Ltd. Hospital - 23.54 23.54 TakTak Watcharasirivej Co.,Ltd. (3) Hospital 21.47 - Chiang rai (and held by Chiang Mai Ram Hospital Co., Ltd. 3.33%, Chiang Mai Ram Medical Business Public Co., Ltd. 1.67% and Theppanya Business Co., Ltd. 0.83%) Significant changes in the preparation of consolidated financial statements for the year ended December 31, 2022, consisted of: (1) Change in status of investment in subsidiary On October 21, 2022, the subsidiary - Hariphunchai Hospital Co., Ltd acquired the investment in Pawo Hospital Co., Ltd. resulting in the subsidiaries’ shareholding proportion in that company to increases from to 50.00% to 56.16%. The investment type was changed from investment in associated company to investment in subsidiary. The subsidiaries have included the financial statements of such acquired company in the preparation of the consolidated financial statements of the subsidiaries since October 21, 2022, onwards. (2) Investment in subsidiary In the third quarter 2022, the subsidiaries acquired the investment in Medica Bangkok Clinic Co., Ltd. resulting in the Company’s shareholding proportion in that company to 60.00% of the shares issued and paid up of such company. The subsidiaries reclassified such investment as an investment in subsidiaries since September 30, 2022, onward. (3) Investment in associated In the second quarter 2022, the subsidiaries acquired the investment in Watcharasirivej Co.,Ltd. resulting in the Company’s shareholding proportion in that company to 30.83% of the shares issued and paid up of such company. The subsidiaries reclassified such investment as an investment in associated company since June 10, 2022, onward. 2.2.2 The Company is deemed to have control over an investee or subsidiaries if it has rights, or is exposed, to variable returns from its involvement with the investee, and it has the ability to direct the activities that affect the amount of its returns. 2.2.3 Subsidiaries are fully consolidated, being the date on which the Company obtains control, and continue to be consolidated until the date when such control ceases. 2.2.4 The accounting period of the investments of subsidiary companies are ended at the same period of Vibhavadi Medical Center Public Co., Ltd. The percentage of shareholding at 99.99% of the subsidiary companies, the Company is treated as holding of 100% of consolidated financial statements and recorded under the cost method. 2.2.5 Accounting policy for subsidiary companies will utilize the same policy as Vibhavadi Medical Center Public Company Limited.Co., Ltd. 2.2.3 2.2.6 Outstanding balances and significant transactions between the Company and its subsidiaries have been eliminated from the consolidated financial statements. 2.2.4 2.2.7 Non-controlling interests represent the portion of profit or loss and net assets of the subsidiaries that are not held by the Company and are presented separately from the portion of owners of the parent. 2.3 Financial reporting standards that became effective in the current period year During the periodyear, the Company and its subsidiaries have has adopted the revised financial reporting standards and interpretations standards, which are effective for fiscal years beginning on or after January 1, 20212022. These financial reporting standards were aimed at alignment with the corresponding International Financial Reporting Standards with most of the changes directed towards clarifying accounting treatment and providing practices, accounting guidance and disclosures in the notes to the financial statements and, for some standards, providing temporary reliefs or temporary exemptions to users of the standards. The adoption of these financial reporting standards does not have any significant impact on the financial statements in the current periodyear. 2.4 Revised Financial reporting standards Reporting Standards that will become effective in the future The Federation of Accounting Professions has revised TFRS 16 lease agreements and published in the Government Gazette on January 27, 2021. There is added the requirements for the temporary exception arising from interest rate benchmark reform, which an entity shall apply these amendments for annual reporting periods financial statements with the accounting period beginning on or after January 1, 2022 2023 The Federation of Accounting Professions has announced to apply several revised financial reporting standards in the Royal Gazette. This will become effective for the financial statements with earlier application permittedthe accounting period beginning on or after January 1, 2023. This revision is for the financial reporting standards to be clearer and more appropriate and to conform with international financial reporting standards. Such revision does not affect the principles of the standards and does not affect the users of the financial reporting standards adopted before 2023. The management of the Company and its subsidiaries are currently evaluating believe that this revision of the impact of these standards to will not significantly affect the financial statements in the year when they are adoptedstatements. 2.5 Cumulative effect from New Financial Reporting Standards The Federation of Accounting Professions has announced to apply the previous period's financial statements before classification and other financial asset value In 2020, the Company set an investment objective Financial Reporting Standard No.17 on “Insurance Contract” in the financial assets type investment in marketable equity Royal Gazette. This standard requires to comply with the nature held for sale as current financial assetsdefined criteria of the international reporting standards including various related improvements. As a result, the Company has The effective date is to reclassify and remeasure other financial assets by restating apply on the financial statements for classification and measurement of such items into profit the accounting period beginning on or loss to follow the objectives of the company. Therefore, the Company has restated the financial statements presented for comparative purposes and presented the consolidated statement of financial position and separate statement of financial position as at after January 1, 2020 for comparative information as if the Company had correctly recorded the accounts. The cumulative effect of such adjustment is presented as a separate item in the statement of changes in shareholder's equity. The amounts of adjustments that have effect on the items in the statement of financial position and statement of comprehensive income are as follows: • Statements of financial position Consolidated financial statements As at December 31, 2020 As at January 1, 2020 As previously reported Adjustment increase (decrease) As restated As previously reported Adjustment increase (decrease) As restated Asset Other current financial asset - 156,910,000 156,910,000 - 56,102,150 56,102,150 Other non-current financial asset 7,900,167,417 (156,910,000) 7,743,257,417 7,360,434,110 (56,102,150) 7,304,331,960 Retained earnings - unappropriated 2,449,130,766 11,749,897 2,460,880,663 2,583,221,873 (3,923,281) 2,579,298,592 Other components of shareholders' equity 1,496,407,944 (11,749,897) 1,484,658,047 1,377,393,221 3,923,281 1,381,316,502 Separate financial statements As at December 31, 2020 As at January 1, 2020 As previously reported Adjustment increase (decrease) As restated As previously reported Adjustment increase (decrease) As restated Asset Other current financial asset - 156,910,000 156,910,000 - 56,102,150 56,102,150 Other non-current financial asset 5,145,443,263 (156,910,000) 4,988,533,263 4,401,296,413 (56,102,150) 4,345,194,263 Retained earnings - unappropriated 980,203,060 11,749,897 991,952,957 1,022,620,856 (3,923,281) 1,018,697,575 Other components of shareholders' equity 738,042,960 (11,749,897) 726,293,063 490,009,847 3,923,281 493,933,128 • Statements of comprehensive income For the three-month periods ended March 31, 2020 Consolidated financial statements Separate financial statements As previously reported Adjustment increase (decrease) As restated As previously reported Adjustment increase (decrease) As restated Loss on fair value measurement of financial assets - (19,501,231) (19,501,231) - (19,501,231) (19,501,231) Profit from operating activities 275,004,361 (19,501,231) 255,503,130 353,967,286 (19,501,231) 334,466,055 Profit before income tax expenses 250,224,650 (19,501,231) 230,723,419 323,799,701 (19,501,231) 304,298,470 Income tax expenses 37,533,625 (3,900,246) 33,633,379 8,716,132 (3,900,246) 4,815,886 Profit for the period 212,691,025 (15,600,985) 197,090,040 315,083,569 (15,600,985) 299,482,584 Loss on investment in equity designated at fair value through other comprehensive income (654,867,821) 19,501,231 (635,366,590) (448,215,238) 19,501,231 (428,714,007) Income tax relating to items that will not be reclassified 130,973,564 (3,900,246) 127,073,318 89,643,047 (3,900,246) 85,742,801 Other comprehensive income (loss) for the period, net of income tax (572,096,680) 15,600,985 (556,495,695) (358,572,191) 15,600,985 (342,971,206) Profit attributable - Owners of the parent 151,048,058 (15,600,985) 135,447,073 315,083,569 (15,600,985) 299,482,584 Basic earnings per share 0.0114 (0.0012) 0.0102 0.0238 (0.0012) 0.0226 Diluted earnings per share 0.0103 (0.0011) 0.0092 0.0214 (0.0010) 0.02042025.

BASIS FOR THE PREPARATION OF FINANCIAL STATEMENTS. 2.1 Basis for preparation of the interim financial statements These interim financial statements are prepared in accordance with Thai Accounting Standard No. 34 Interim Financial Reporting, and the requirements of the Securities and Exchange Commission (SEC). The interim financial statements are intended to provide information additional to that included in the latest annual financial statements. Accordingly, they focus on new activities, events, and situations and not intended to re-emphasis on the information previously reported. The interim financial statements should therefore, be read in conjunction with the financial statements for the year ended December 31, 20202021. The interim financial statements have been prepared on a historical cost basis except where otherwise disclosed in the accounting policies. The interim financial statements in Thai language are the official statutory financial statements of the Company. The interim financial statements in English language have been translated from the financial statements in Thai language version. 2.2 Basis for the preparation of consolidated financial statements 2.2.1 The consolidated financial statements have included the financial statements of Vibhavadi Medical Center Public Co., Ltd., subsidiaries and associated companies as follows; Percentage of holding % of share capital Name of Company Type of business As at March 31June 30, 2021 2022 As at December 31, 2020 2021 Head office location Chiang Mai Ram Medical Business Public Co., Ltd. Hospital 83.55 83.55 Chiang Mai Beauty Design Center Co., Ltd. Beauty Business 50.00 50.00 Bangkok V.precision V precision Co., Ltd. Anti Aging Center 70.00 70.00 Bangkok Percentage of holding % of share capital Name of Company Type of business As at March 31June 30, 2021 2022 As at December 31, 2020 2021 Head office location Vibharam Hospital Co., Ltd. Hospital 33.73 33.73 33.85 33.85 Bangkok Thippayabadin Co., Ltd. Trading medical 38.18 38.18 40.57 40.57 Bangkok instruments Bangpo General Hospital Co., Ltd. Hospital 28.57 28.57 Bangkok Chiang Mai Ram Hospital Co., Ltd. Hospital 47.09 47.09 Chiang Mai Hariphunchai Memorial Co., Ltd. Hospital 72.43 72.43 Lamphun Theppanya Business Co., Ltd. Hospital 47.09 47.09 Chiang Mai Ramkhamhaeng Chiangmai Hospital Co., Ltd. Hospital 45.14 45.14 45.53 45.53 Chiang Mai (and held by Chiang Mai Ram Medical Business Public Co., Ltd. 18%) Khelang Nakorn Hospital Co., Ltd. Hospital 11.99 11.99 Lampang Pawo Hospital Co., Ltd. Hospital 23.54 23.54 TakTak Watcharasirivej Co.,Ltd.* Hospital 00.00 - Xxxxxx rai ( and held by Chiang Mai Ram Hospital Co., Ltd. 3.33%, Chiang Mai Ram Medical Business Public Co., Ltd. 1.67% and Theppanya Business Co., Ltd. 0.83%) * In second quarter 2022, the subsidiaries acquired the investment in Watcharasirivej Co.,Ltd. resulting in the Company’s shareholding proportion in that company to 30.83% of the shares issued and paid up of such company. The subsidiaries reclassified such investment as an investment in associated company since June 10, 2022, onward. 2.2.2 Accounting policy for subsidiary companies will utilize the same policy as Vibhavadi Medical Center Public Company Limitedthe parent company. 2.2.3 Outstanding balances and significant transactions between the Company and its subsidiaries have been eliminated from the consolidated financial statements. 2.2.4 Non-controlling interests represent the portion of profit or loss and net assets of the subsidiaries that are not held by the Company and are presented separately from the portion of owners of the parent. 2.3 Financial reporting standards that became effective in the current period During the period, the Company and its subsidiaries have Group has adopted the revised financial reporting standards and interpretations standards, which are effective for fiscal years beginning on or after January 1, 20212022. These financial reporting standards were aimed at alignment with the corresponding International Financial Reporting Standards with most of the changes directed towards clarifying accounting treatment and providing practices, accounting guidance and disclosures in the notes to the financial statements and, for some standards, providing temporary reliefs or temporary exemptions to users of the standards. The adoption of these financial reporting standards does not have any significant impact on the financial statements in the current period. 2.4 Financial reporting standards that will become effective in the future The Federation of Accounting Professions has revised TFRS 16 lease agreements and published in the Government Gazette on January 27, 2021. There is added the requirements for the temporary exception arising from interest rate benchmark reform, which an entity shall apply these amendments for annual reporting periods beginning on or after January 1, 2022 with earlier application permitted. The management of the Company and its subsidiaries are currently evaluating the impact of these standards to the financial statements in the year when they are adopted. 2.5 Cumulative effect from the previous period's financial statements before classification and other financial asset value In 2020, the Company set an investment objective in the financial assets type investment in marketable equity with the nature held for sale as current financial assets. As a result, the Company has to reclassify and remeasure other financial assets by restating the financial statements for classification and measurement of such items into profit or loss to follow the objectives of the company. Therefore, the Company has restated the financial statements presented for comparative purposes and presented the consolidated statement of financial position and separate statement of financial position as at January 1, 2020 for comparative information as if the Company had correctly recorded the accounts. The cumulative effect of such adjustment is presented as a separate item in the statement of changes in shareholder's equity. The amounts of adjustments that have effect on the items in the statement of financial position and statement of comprehensive income are as follows: • Statements of financial position Consolidated financial statements As at December 31, 2020 As at January 1, 2020 As previously reported Adjustment increase (decrease) As restated As previously reported Adjustment increase (decrease) As restated Asset Other current financial asset - 156,910,000 156,910,000 - 56,102,150 56,102,150 Other non-current financial asset 7,900,167,417 (156,910,000) 7,743,257,417 7,360,434,110 (56,102,150) 7,304,331,960 Retained earnings - unappropriated 2,449,130,766 11,749,897 2,460,880,663 2,583,221,873 (3,923,281) 2,579,298,592 Other components of shareholders' equity 1,496,407,944 (11,749,897) 1,484,658,047 1,377,393,221 3,923,281 1,381,316,502 Separate financial statements As at December 31, 2020 As at January 1, 2020 As previously reported Adjustment increase (decrease) As restated As previously reported Adjustment increase (decrease) As restated Asset Other current financial asset - 156,910,000 156,910,000 - 56,102,150 56,102,150 Other non-current financial asset 5,145,443,263 (156,910,000) 4,988,533,263 4,401,296,413 (56,102,150) 4,345,194,263 Retained earnings - unappropriated 980,203,060 11,749,897 991,952,957 1,022,620,856 (3,923,281) 1,018,697,575 Other components of shareholders' equity 738,042,960 (11,749,897) 726,293,063 490,009,847 3,923,281 493,933,128 • Statements of comprehensive income For the three-month periods ended March 31, 2020 Consolidated financial statements Separate financial statements As previously reported Adjustment increase (decrease) As restated As previously reported Adjustment increase (decrease) As restated Loss on fair value measurement of financial assets - (19,501,231) (19,501,231) - (19,501,231) (19,501,231) Profit from operating activities 275,004,361 (19,501,231) 255,503,130 353,967,286 (19,501,231) 334,466,055 Profit before income tax expenses 250,224,650 (19,501,231) 230,723,419 323,799,701 (19,501,231) 304,298,470 Income tax expenses 37,533,625 (3,900,246) 33,633,379 8,716,132 (3,900,246) 4,815,886 Profit for the period 212,691,025 (15,600,985) 197,090,040 315,083,569 (15,600,985) 299,482,584 Loss on investment in equity designated at fair value through other comprehensive income (654,867,821) 19,501,231 (635,366,590) (448,215,238) 19,501,231 (428,714,007) Income tax relating to items that will not be reclassified 130,973,564 (3,900,246) 127,073,318 89,643,047 (3,900,246) 85,742,801 Other comprehensive income (loss) for the period, net of income tax (572,096,680) 15,600,985 (556,495,695) (358,572,191) 15,600,985 (342,971,206) Profit attributable - Owners of the parent 151,048,058 (15,600,985) 135,447,073 315,083,569 (15,600,985) 299,482,584 Basic earnings per share 0.0114 (0.0012) 0.0102 0.0238 (0.0012) 0.0226 Diluted earnings per share 0.0103 (0.0011) 0.0092 0.0214 (0.0010) 0.0204

BASIS FOR THE PREPARATION OF FINANCIAL STATEMENTS. 2.1 Basis for preparation of the interim financial statements These interim The financial statements are have been prepared in accordance with the accounting standards prescribed by Thai Accounts Act enunciated under the Accounting Standard No. 34 Interim Profession Act B.E.2547 by complying with Thai Financial Reporting, and the requirements of the Securities and Exchange Commission (SEC)Reporting Standards. The interim financial statements are intended to provide information additional to that included in the latest annual financial statements. Accordingly, they focus on new activities, events, and situations and not intended to re-emphasis on the information previously reported. The interim financial statements should therefore, be read in conjunction with presentation of the financial statements has been made in compliance with the Notification of the Department of Business Development, the Ministry of Commerce, re : the financial statements presentation for public limited company, issued under the year ended December 31, 2020Accounting Act B.E. 2543. The interim financial statements have been prepared on a historical cost basis except where otherwise disclosed in the accounting policies. The interim financial statements in Thai language are the official statutory financial statements of the Company. The interim financial statements in English language have been translated from the such financial statements in Thai language versionlanguage. 2.2 Basis for the preparation of consolidated financial statements 2.2.1 The consolidated financial statements have included the financial statements of Vibhavadi Medical Center Public Co., Ltd., subsidiaries and associated companies as follows; Type of Percentage of holding % of share capital Name of Company Type of business As at March 31, 2021 As at December 31, 2020 Head office location Chiang Mai Ram Medical Business Public Co., Ltd. Hospital 83.55 83.55 Chiang Mai Beauty Design Center Co., Ltd. ** Beauty Business 50.00 50.00 Bangkok V.precision Co., Ltd. Anti Aging Center 70.00 70.00 - Bangkok Type of Percentage of holding % of share capital Name of Company Type of business As at March 31, 2021 As at December 31, 2020 Head office location Vibharam Hospital Co., Ltd. Hospital 33.73 33.73 40.76 Bangkok Thippayabadin Co., Ltd. Trading medical 38.18 38.18 33.33 Bangkok instruments Bangpo General Hospital Co., Ltd. Hospital 28.57 28.57 Bangkok Chiang Mai Ram Hospital Co., Ltd. Hospital 47.09 47.09 Chiang Mai Hariphunchai Memorial Co., Ltd. Hospital 72.43 72.43 Lamphun Theppanya Business Co., Ltd. Hospital 47.09 47.09 Chiang Mai Ramkhamhaeng Chiangmai Hospital Co., Ltd. Ltd.* Hospital 45.14 45.14 Chiang Mai Khelang Nakorn Hospital Co., Ltd. Hospital 11.99 11.99 Lampang Pawo Hospital Co., Ltd. Hospital 23.54 23.54 TakTak * According to the Board of Directors’ subsidiary Meeting No. 7/2018 dated December 25, 2018, it had the resolution for Chiang Mai Ram Medical Business Public Co., Ltd. and Chiang Mai Ram Hospital Co., Ltd. to invest in Ramkhamhaeng Chiangmai Hospital Co., Ltd. On March 1, 2019, its subsidiary had held the shares in such company for 18% and the indirect subsidiary - Chiang Mai Ram Hospital Co., Ltd. had held the shares for 63% totaled 81%. From investing and having control over such business, it had resulted for Xxxxxxxxxxxx Chiangmai Hospital Co., Ltd. to be considered as the subsidiary of Chiang Mai Ram Hospital Co., Ltd. The subsidiaries have adopted the financial statements of such companies to prepare the consolidated financial statements from the first quarter of 2019, onwards. On May 2, 2019, such company has call up Baht 7 per share, from its subsidiary - Chiang Mai Ram Medical Business Public Co., Ltd. had paid for the shares amounted Baht 50.40 million and from the indirect subsidiary - Chiang Mai Ram Hospital Co., Ltd. had paid for the shares amounted Baht 179.79 million totaled Baht 230.19 million, resulting in indirect subsidiary - Chiang Mai Ram Hospital Co., Ltd. held in that company to increase from 63.00% to 63.85% totaled 81.85%. And on July 26, 2019, such company has registered the capital increase for 4 million shares at Baht 10 per share, amounted Baht 40.00 million. Its subsidiary - Chiang Mai Ram Medical Business Public Co., Ltd. had paid the shares amounted Baht 7.20 million and from the indirect subsidiary, Chiang Mai Ram Hospital Co., Ltd. had paid the shares amounted Baht 25.82 million totaled Baht 33.02 million, resulting in the indirect subsidiary - Chiang Mai Ram Hospital Co., Ltd. held in such company to increase from 63.85% to 63.91% totaled 81.91%. On February 24, 2020, Ramkhamhaeng Chiangmai Hospital Co., Ltd. had registered the capital increase for 56 million shares at Baht 10 per share, amounted Baht 560 million. Chiang Mai Ram Medical Business Public Company Limited had paid the share amounted Baht 40.32 million and from its subsidiary, Chiang Mai Ram Hospital Co., Ltd. amounted Baht 146.48 million totaled Baht 186.80 million, resulting in subsidiary - Chiang Mai Ram Hospital Co., Ltd. Held in that company to increase from 63.91% to 64.74% totaled of the group subsidiaries in held 82.74%. ** According to the Board of Directors’ Extra Meeting No. 4/2019 dated September 25, 2019, it had the adjustment of investment structure to approved the Princeton Park Suites Co., Ltd. transfer all of shares of Beauty Design Center Co., Ltd., of shareholding 50 percent to be considered as the subsidiary and Legacy Golf (Thailand) Co., Ltd. of shareholding 10 percent to be considered as the other long-term investments to the company as discussed in Note 12 to the financial statements. 2.2.2 Accounting policy for subsidiary companies will utilize the same policy as Vibhavadi Medical Center Public Company Limited. 2.2.3 Outstanding balances and significant transactions between the Company and its subsidiaries have been eliminated from the consolidated financial statements. 2.2.4 Non-controlling interests represent the portion of profit or loss and net assets of the subsidiaries that are not held by the Company and are presented separately from the portion of owners of the parent. 2.3 Financial reporting standards that became effective in the current period year During the periodyear, the Company and its subsidiaries have adopted the revised and new financial reporting standards standards, interpretations and interpretations the accounting guidance, which are effective for fiscal years beginning on or after January 1, 20212020. These financial reporting standards were aimed at alignment with the corresponding International Financial Reporting Standards with most of the changes directed towards clarifying accounting treatment and providing accounting guidance for users of the standards. The adoption Except, the new standard involves changes to key principles, as summarized below. TFRS 7 Financial Instruments: Disclosures TFRS 9 Financial Instruments TAS 32 Financial Instruments: Presentation TFRIC 16 Xxxxxx of these a Net Investment in a Foreign Operation TFRIC 19 Extinguishing Financial Liabilities with Equity Instruments A set of TFRSs related to financial reporting standards does not have any significant impact on the financial statements in the current period. 2.4 Financial reporting standards that will become effective in the future The Federation of Accounting Professions has revised TFRS 16 lease agreements and published in the Government Gazette on January 27, 2021. There is added the requirements for the temporary exception arising from interest rate benchmark reforminstruments, which an entity shall apply these amendments for annual reporting periods beginning on consists of five accounting standards and interpretations, as follows: These TFRSs related to financial instruments make stipulations relating to the classification of financial instruments and their measurement at fair value or after January 1amortized cost (taking into account the type of instrument, 2022 with earlier application permittedthe characteristics of the contractual cash flows and the Company’s business model), calculation of impairment using the expected credit loss method, and hedge accounting. These include stipulations regarding the presentation and disclosure of financial instruments. When the TFRSs related to financial instruments are effective, some accounting standards, interpretations and guidance which are currently effective will be cancelled. The management of the Company and its subsidiaries are currently evaluating has adopted TFRS related to financial instruments the impact first-time in its financial statements by applying modified retrospective approach of these standards adoption of which the cumulative effect as an adjustment to the financial statements in the year when they are adopted. 2.5 Cumulative effect from the previous period's financial statements before classification and other financial asset value In 2020, the Company set an investment objective in the financial assets type investment in marketable equity with the nature held for sale as current financial assets. As a result, the Company has to reclassify and remeasure other financial assets by restating the financial statements for classification and measurement of such items into profit or loss to follow the objectives of the company. Therefore, the Company has restated the financial statements presented for comparative purposes and presented the consolidated statement of financial position and separate statement of financial position retained earnings as at January 1, 2020 for and the comparative information as if the Company had correctly recorded the accountswas not restated. The cumulative effect of such adjustment the change is presented as a separate item described in Note 5 to the statement of changes in shareholder's equity. The amounts of adjustments that have effect on the items in the statement of financial position and statement of comprehensive income are as follows: • Statements of financial position Consolidated financial statements As at December 31, 2020 As at January 1, 2020 As previously reported Adjustment increase (decrease) As restated As previously reported Adjustment increase (decrease) As restated Asset Other current financial asset - 156,910,000 156,910,000 - 56,102,150 56,102,150 Other non-current financial asset 7,900,167,417 (156,910,000) 7,743,257,417 7,360,434,110 (56,102,150) 7,304,331,960 Retained earnings - unappropriated 2,449,130,766 11,749,897 2,460,880,663 2,583,221,873 (3,923,281) 2,579,298,592 Other components of shareholders' equity 1,496,407,944 (11,749,897) 1,484,658,047 1,377,393,221 3,923,281 1,381,316,502 Separate financial statements As at December 31, 2020 As at January 1, 2020 As previously reported Adjustment increase (decrease) As restated As previously reported Adjustment increase (decrease) As restated Asset Other current financial asset - 156,910,000 156,910,000 - 56,102,150 56,102,150 Other non-current financial asset 5,145,443,263 (156,910,000) 4,988,533,263 4,401,296,413 (56,102,150) 4,345,194,263 Retained earnings - unappropriated 980,203,060 11,749,897 991,952,957 1,022,620,856 (3,923,281) 1,018,697,575 Other components of shareholders' equity 738,042,960 (11,749,897) 726,293,063 490,009,847 3,923,281 493,933,128 • Statements of comprehensive income For the three-month periods ended March 31, 2020 Consolidated financial statements Separate financial statements As previously reported Adjustment increase (decrease) As restated As previously reported Adjustment increase (decrease) As restated Loss on fair value measurement of financial assets - (19,501,231) (19,501,231) - (19,501,231) (19,501,231) Profit from operating activities 275,004,361 (19,501,231) 255,503,130 353,967,286 (19,501,231) 334,466,055 Profit before income tax expenses 250,224,650 (19,501,231) 230,723,419 323,799,701 (19,501,231) 304,298,470 Income tax expenses 37,533,625 (3,900,246) 33,633,379 8,716,132 (3,900,246) 4,815,886 Profit for the period 212,691,025 (15,600,985) 197,090,040 315,083,569 (15,600,985) 299,482,584 Loss on investment in equity designated at fair value through other comprehensive income (654,867,821) 19,501,231 (635,366,590) (448,215,238) 19,501,231 (428,714,007) Income tax relating to items that will not be reclassified 130,973,564 (3,900,246) 127,073,318 89,643,047 (3,900,246) 85,742,801 Other comprehensive income (loss) for the period, net of income tax (572,096,680) 15,600,985 (556,495,695) (358,572,191) 15,600,985 (342,971,206) Profit attributable - Owners of the parent 151,048,058 (15,600,985) 135,447,073 315,083,569 (15,600,985) 299,482,584 Basic earnings per share 0.0114 (0.0012) 0.0102 0.0238 (0.0012) 0.0226 Diluted earnings per share 0.0103 (0.0011) 0.0092 0.0214 (0.0010) 0.0204statements.

BASIS FOR THE PREPARATION OF FINANCIAL STATEMENTS. 2.1 Basis for preparation of the interim financial statements These interim The financial statements are have been prepared in accordance with the accounting standards prescribed by Thai Accounts Act enunciated under the Accounting Standard No. 34 Interim Profession Act B.E.2547 by complying with Thai Financial Reporting, and the requirements of the Securities and Exchange Commission (SEC)Reporting Standards. The interim financial statements are intended to provide information additional to that included in the latest annual financial statements. Accordingly, they focus on new activities, events, and situations and not intended to re-emphasis on the information previously reported. The interim financial statements should therefore, be read in conjunction with presentation of the financial statements has been made in compliance with the Notification of the Department of Business Development, the Ministry of Commerce, re : the financial statements presentation for public limited company, issued under the year ended December 31, 2020Accounting Act B.E. 2543. The interim financial statements have been prepared on a historical cost basis except where otherwise disclosed in the accounting policies. The interim financial statements in Thai language are the official statutory financial statements of the Company. The interim financial statements in English language have been translated from the such financial statements in Thai language versionlanguage. 2.2 Basis for the preparation of consolidated financial statements 2.2.1 The consolidated financial statements have included the financial statements of Vibhavadi Medical Center Public Co., Ltd., subsidiaries and associated companies as follows; Type of Percentage of holding % of share capital Name of Company Type of business As at March 31, 2021 As at December 31, 2020 Head office location Chiang Mai Ram Medical Business Public Co., Ltd. Hospital 83.55 83.55 Chiang Mai Beauty Design Center Co., Ltd. ** Beauty Business 50.00 50.00 - Bangkok V.precision Co., Ltd. Anti Aging Center 70.00 70.00 Bangkok Percentage of holding % of share capital Name of Company Type of business As at March 31, 2021 As at December 31, 2020 Head office location Vibharam Hospital Co., Ltd. Hospital 33.73 33.73 40.75 40.75 Bangkok Thippayabadin Co., Ltd. Trading medical 38.18 38.18 33.33 33.33 Bangkok instruments Bangpo General Hospital Co., Ltd. Hospital 28.57 28.57 Bangkok Type of Percentage of holding % of share capital Head office Company name business 2019 2018 location Indirect subsidiary and associated companies Chiang Mai Ram Hospital Co., Ltd. Hospital 47.09 47.09 Chiang Mai Hariphunchai Memorial Co., Ltd. Hospital 72.43 72.43 Lamphun held by Princeton Park Suites Co., Ltd. Subsidiary company Beauty Design Center Co., Ltd. ** Beauty Business - 50.00 Bangkok held by Chiang Mai Ram Hospital Co.,Ltd. Theppanya Business Co., Ltd. Hospital 47.09 47.09 Chiang Mai Ramkhamhaeng Chiangmai Hospital Co., Ltd. Ltd.* Hospital 45.14 45.14 - Chiang Mai ociated company Khelang Nakorn Hospital Co., Ltd. Hospital 11.99 11.99 Lampang Pawo Hospital Co., Ltd. Hospital 23.54 23.54 TakTak * According to the Board of Directors’ subsidiary Meeting No. 7/2018 dated December 25, 2018, it had the resolution for Chiang Mai Ram Medical Business Public Co., Ltd. and Chiang Mai Ram Hospital Co., Ltd. to invest in Ramkhamhaeng Chiangmai Hospital Co., Ltd. On March 1, 2019, its subsidiary had held the shares in such company for 18% and the indirect subsidiary - Chiang Mai Ram Hospital Co., Ltd. had held the shares for 63% totaled 81%. From investing and having control over such business, it had resulted for Xxxxxxxxxxxx Chiangmai Hospital Co., Ltd. to be considered as the subsidiary of Chiang Mai Ram Hospital Co., Ltd. The subsidiaries have adopted the financial statements of such companies to prepare the consolidated financial statements from the first quarter of 2019, onwards. On May 2, 2019, such company has call up Baht 7 per share, from its subsidiary - Chiang Mai Ram Medical Business Public Co., Ltd. had paid for the shares amounted Baht 50.40 million and from the indirect subsidiary - Chiang Mai Ram Hospital Co., Ltd. had paid for the shares amounted Baht 179.79 million totaled Baht 230.19 million, resulting in indirect subsidiary - Chiang Mai Ram Hospital Co., Ltd. held in that company to increase from 63.00% to 63.85% totaled 81.85%. And on July 26, 2019, such company has registered the capital increase for 4 million shares at Baht 10 per share, amounted Baht 40.00 million. Its subsidiary - Chiang Mai Ram Medical Business Public Co., Ltd. had paid the shares amounted Baht 7.20 million and from the indirect subsidiary, Chiang Mai Ram Hospital Co., Ltd. had paid the shares amounted Baht 25.82 million totaled Baht 33.02 million, resulting in the indirect subsidiary - Chiang Mai Ram Hospital Co., Ltd. held in such company to increase from 63.85% to 63.91% totaled 81.91%. ** According to the Board of Directors’ Extra Meeting No. 4/2019 dated September 25, 2019, it had the adjustment of investment structure to approved the Princeton Park Suites Co., Ltd. transfer all of shares of Beauty Design Center Co., Ltd., of shareholding 50 percent to be considered as the subsidiary and Legacy Golf (Thailand) Co., Ltd. of shareholding 10 percent to be considered as the other long-term investments to the company as discussed in Note 12 to the financial statements. 2.2.2 Accounting policy for subsidiary companies will utilize the same policy as Vibhavadi Medical Center Public Company Limited. 2.2.3 Outstanding balances and significant transactions between the Company and its subsidiaries have been eliminated from the consolidated financial statements. 2.2.4 Non-controlling interests represent the portion of profit or loss and net assets of the subsidiaries that are not held by the Company and are presented separately from the portion of owners of the parent. 2.3 Financial reporting standards that became effective in the current period year During the periodyear, the Company and its subsidiaries have adopted the revised (revised 2018) and new financial reporting standards and interpretations interpretations, which are effective for fiscal years beginning on or after January 1, 20212019. These financial reporting standards were aimed at alignment with the corresponding International Financial Reporting Standards with most of the changes and clarifications directed towards disclosures in the notes to financial statements. The adoption of these financial reporting standards does not have any significant impact on the Company and its subsidiaries’ financial statements. 2.4 Financial reporting standards that will become effective in the future During the year, the Federation of Accounting Professions issued a number of new and revised financial reporting standards and interpretations, which are effective for fiscal years beginning on or after January 1, 2020. These financial reporting standards were aimed at alignment with the corresponding International Financial Reporting Standards with most of the changes directed towards clarifying accounting treatment and providing accounting guidance for users of the standards. The adoption Except, the new standard involves changes to key principles, as summarized below. A set of these TFRSs related to financial reporting standards does not have any significant impact on the financial statements in the current period. 2.4 Financial reporting standards that will become effective in the future The Federation of Accounting Professions has revised TFRS 16 lease agreements and published in the Government Gazette on January 27, 2021. There is added the requirements for the temporary exception arising from interest rate benchmark reforminstruments, which an entity shall apply these amendments for annual reporting periods beginning on or after January 1consists of five accounting standards and interpretations, 2022 with earlier application permitted. The management of the Company and its subsidiaries are currently evaluating the impact of these standards to the financial statements in the year when they are adopted. 2.5 Cumulative effect from the previous period's financial statements before classification and other financial asset value In 2020, the Company set an investment objective in the financial assets type investment in marketable equity with the nature held for sale as current financial assets. As a result, the Company has to reclassify and remeasure other financial assets by restating the financial statements for classification and measurement of such items into profit or loss to follow the objectives of the company. Therefore, the Company has restated the financial statements presented for comparative purposes and presented the consolidated statement of financial position and separate statement of financial position as at January 1, 2020 for comparative information as if the Company had correctly recorded the accounts. The cumulative effect of such adjustment is presented as a separate item in the statement of changes in shareholder's equity. The amounts of adjustments that have effect on the items in the statement of financial position and statement of comprehensive income are as follows: • Statements of financial position Consolidated financial statements As at December 31, 2020 As at January 1, 2020 As previously reported Adjustment increase (decrease) As restated As previously reported Adjustment increase (decrease) As restated Asset Other current financial asset - 156,910,000 156,910,000 - 56,102,150 56,102,150 Other non-current financial asset 7,900,167,417 (156,910,000) 7,743,257,417 7,360,434,110 (56,102,150) 7,304,331,960 Retained earnings - unappropriated 2,449,130,766 11,749,897 2,460,880,663 2,583,221,873 (3,923,281) 2,579,298,592 Other components of shareholders' equity 1,496,407,944 (11,749,897) 1,484,658,047 1,377,393,221 3,923,281 1,381,316,502 Separate financial statements As at December 31, 2020 As at January 1, 2020 As previously reported Adjustment increase (decrease) As restated As previously reported Adjustment increase (decrease) As restated Asset Other current financial asset - 156,910,000 156,910,000 - 56,102,150 56,102,150 Other non-current financial asset 5,145,443,263 (156,910,000) 4,988,533,263 4,401,296,413 (56,102,150) 4,345,194,263 Retained earnings - unappropriated 980,203,060 11,749,897 991,952,957 1,022,620,856 (3,923,281) 1,018,697,575 Other components of shareholders' equity 738,042,960 (11,749,897) 726,293,063 490,009,847 3,923,281 493,933,128 • Statements of comprehensive income For the three-month periods ended March 31, 2020 Consolidated financial statements Separate financial statements As previously reported Adjustment increase (decrease) As restated As previously reported Adjustment increase (decrease) As restated Loss on fair value measurement of financial assets - (19,501,231) (19,501,231) - (19,501,231) (19,501,231) Profit from operating activities 275,004,361 (19,501,231) 255,503,130 353,967,286 (19,501,231) 334,466,055 Profit before income tax expenses 250,224,650 (19,501,231) 230,723,419 323,799,701 (19,501,231) 304,298,470 Income tax expenses 37,533,625 (3,900,246) 33,633,379 8,716,132 (3,900,246) 4,815,886 Profit for the period 212,691,025 (15,600,985) 197,090,040 315,083,569 (15,600,985) 299,482,584 Loss on investment in equity designated at fair value through other comprehensive income (654,867,821) 19,501,231 (635,366,590) (448,215,238) 19,501,231 (428,714,007) Income tax relating to items that will not be reclassified 130,973,564 (3,900,246) 127,073,318 89,643,047 (3,900,246) 85,742,801 Other comprehensive income (loss) for the period, net of income tax (572,096,680) 15,600,985 (556,495,695) (358,572,191) 15,600,985 (342,971,206) Profit attributable - Owners of the parent 151,048,058 (15,600,985) 135,447,073 315,083,569 (15,600,985) 299,482,584 Basic earnings per share 0.0114 (0.0012) 0.0102 0.0238 (0.0012) 0.0226 Diluted earnings per share 0.0103 (0.0011) 0.0092 0.0214 (0.0010) 0.0204:

BASIS FOR THE PREPARATION OF FINANCIAL STATEMENTS. 2.1 Basis for preparation of the interim financial statements These interim financial statements are prepared in accordance with Thai Accounting Standard No. 34 Interim Financial Reporting, and the requirements of the Securities and Exchange Commission (SEC). The interim financial statements are intended to provide information additional to that included in the latest annual financial statements. Accordingly, they focus on new activities, events, and situations and not intended to re-emphasis on the information previously reported. The interim financial statements should therefore, be read in conjunction with the financial statements for the year ended December 31, 2020. The interim financial statements have been prepared on a historical cost basis except where otherwise disclosed in the accounting policies. The interim financial statements in Thai language are the official statutory financial statements of the Company. The interim financial statements in English language have been translated from the financial statements in Thai language version. 2.2 Basis for the preparation of consolidated financial statements 2.2.1 The consolidated financial statements have included the financial statements of Vibhavadi Medical Center Public Co., Ltd., subsidiaries and associated companies as follows; Percentage of holding % of share capital Name of Company Type of business As at March 31June 30, 2021 As at December 31, 2020 Head office location Chiang Mai Ram Medical Business Public Co., Ltd. Hospital 83.55 83.55 Chiang Mai Beauty Design Center Co., Ltd. Beauty Business 50.00 50.00 Bangkok V.precision Co., Ltd. Anti Aging Center 70.00 70.00 Bangkok Percentage of holding % of share capital Name of Company Type of business As at March 31, 2021 As at December 31, 2020 Head office location Vibharam Hospital Co., Ltd. Hospital 33.73 33.73 Bangkok Thippayabadin Co., Ltd. Trading medical 38.18 38.18 Bangkok instruments Bangpo General Hospital Co., Ltd. Hospital 28.57 28.57 Bangkok Chiang Mai Ram Hospital Co., Ltd. Hospital 47.09 47.09 Chiang Mai Hariphunchai Memorial Co., Ltd. Hospital 72.43 72.43 Lamphun Theppanya Business Co., Ltd. Hospital 47.09 47.09 Chiang Mai Ramkhamhaeng Chiangmai Hospital Co., Ltd. Hospital 45.14 45.14 Chiang Mai Khelang Nakorn Hospital Co., Ltd. Hospital 11.99 11.99 Lampang Pawo Hospital Co., Ltd. Hospital 23.54 23.54 Tak 2.2.2 Accounting policy for subsidiary companies will utilize the same policy as Vibhavadi Medical Center Public Company Limited. 2.2.3 Outstanding balances and significant transactions between the Company and its subsidiaries have been eliminated from the consolidated financial statements. 2.2.4 Non-controlling interests represent the portion of profit or loss and net assets of the subsidiaries that are not held by the Company and are presented separately from the portion of owners of the parent. 2.3 Financial reporting standards that became effective in the current period During the period, the Company and its subsidiaries have adopted the revised financial reporting standards and interpretations which are effective for fiscal years beginning on or after January 1, 2021. These financial reporting standards were aimed at alignment with the corresponding International Financial Reporting Standards with most of the changes directed towards clarifying accounting treatment and providing accounting guidance for users of the standards. However, COVID-19 Related Rent Concessions beyond June 30, 2021 were adjusted in the financial reporting standard No.16 lease effective from April 1, 2021. Therefore, it is permitted for the company to adopt before the effective date. Such adjustment is a relief of practice, the lessee does not necessarily have to assess that the consent to reduce the rent is a change of lease agreement or not. The consent to reduce the rent is a direct result of the Coronavirus 2019 pandemic (COVID-19) and that falls under the condition specified (revised paragraph 46 khor.2 from formerly June 30, 2021 to June 30, 2022). The recording of the consent to reduce the rent is as if “not a change of the lease”, which during the period, the Federation of Accounting Professions has issued and published in the Government Gazette. The adoption of these financial reporting standards does not have any significant impact on the financial statements in the current period. 2.4 Financial reporting standards that will become effective in the future The Federation of Accounting Professions has issued several revised TFRS 16 lease agreements financial reporting standards and has been published in the Government Gazette on January 27, 2021. There is added the requirements for the temporary exception arising from interest rate benchmark reformGazette, which an entity shall apply these amendments are effective for annual reporting periods fiscal years beginning on or after 1 January 12022. These financial reporting standards were aimed at alignment with the corresponding International Financial Reporting Standards with most of the changes directed towards clarifying accounting treatment and for some financial reporting standards, 2022 with earlier application permittedproviding temporary reliefs or temporary exemptions for users. The management of the Company and its subsidiaries are currently evaluating the impact of these standards to the financial statements in the year when they are adopted. 2.5 Cumulative effect from the previous period's financial statements before classification and other financial asset value In 2020, the Company set an investment objective in the financial assets type investment in marketable equity with the nature held for sale as current financial assets. As a result, the Company has to reclassify and remeasure other financial assets by restating the financial statements for classification and measurement of such items into profit or loss to follow the objectives of the company. Therefore, the Company has restated the financial statements presented for comparative purposes and presented the consolidated statement of financial position and separate statement of financial position as at January 1, 2020 for comparative information as if the Company had correctly recorded the accounts. The cumulative effect of such adjustment is presented as a separate item in the statement of changes in shareholder's equity. The amounts of adjustments that have effect on the items in the statement of financial position and statement of comprehensive income are as follows: • Statements of financial position Consolidated financial statements As at December 31, 2020 As at January 1, 2020 As previously reported Adjustment increase (decrease) As restated As previously reported Adjustment increase (decrease) As restated Asset Other current financial asset - 156,910,000 156,910,000 - 56,102,150 56,102,150 Other non-current financial asset 7,900,167,417 (156,910,000) 7,743,257,417 7,360,434,110 (56,102,150) 7,304,331,960 Retained earnings - unappropriated 2,449,130,766 11,749,897 2,460,880,663 2,583,221,873 (3,923,281) 2,579,298,592 Other components of shareholders' equity 1,496,407,944 (11,749,897) 1,484,658,047 1,377,393,221 3,923,281 1,381,316,502 Separate financial statements As at December 31, 2020 As at January 1, 2020 As previously reported Adjustment increase (decrease) As restated As previously reported Adjustment increase (decrease) As restated Asset Other current financial asset - 156,910,000 156,910,000 - 56,102,150 56,102,150 Other non-current financial asset 5,145,443,263 (156,910,000) 4,988,533,263 4,401,296,413 (56,102,150) 4,345,194,263 Retained earnings - unappropriated 980,203,060 11,749,897 991,952,957 1,022,620,856 (3,923,281) 1,018,697,575 Other components of shareholders' equity 738,042,960 (11,749,897) 726,293,063 490,009,847 3,923,281 493,933,128 • Statements of comprehensive income For the three-month periods ended March 31June 30, 2020 Consolidated financial statements Separate financial statements As previously reported Adjustment increase (decrease) As restated As previously reported Adjustment increase (decrease) As restated Loss on fair value measurement of financial assets - (19,501,231) (19,501,231) 28,306,855 28,306,855 - (19,501,231) (19,501,231) 28,306,855 28,306,855 Profit from operating activities 275,004,361 94,394,227 28,306,855 122,701,082 78,113,345 28,306,855 106,420,200 Profit (19,501,231loss)before income tax expenses (60,757,419) 255,503,130 353,967,286 28,306,855 (19,501,23132,450,564) 334,466,055 50,583,406 28,306,855 78,890,261 Income tax expenses 4,421,444 5,661,371 10,082,815 85,229 5,661,371 5,746,600 Profit (loss) for the period (65,178,863) 22,645,484 (42,533,379) 50,498,177 22,645,484 73,143,661 Loss on investment in equity designated at fair value through other comprehensive income 331,591,764 (28,306,855) 303,284,909 346,228,661 (28,306,855) 317,921,806 Income tax relating to items that will not be reclassified (66,318,373) 5,661,371 (60,657,002) (69,245,732) 5,661,371 (63,584,361) Other comprehensive income (loss) for the period, net of income tax 282,290,891 (22,645,484) 259,645,407 276,982,929 (22,645,484) 254,337,445 Profit (loss) attributable - Owners of the parent (60,416,446) 22,645,484 (37,770,962) 50,498,177 22,645,484 73,143,661 Basic earnings per share (0.0046) 0.0018 (0.0028) 0.0038 0.0017 0.0055 Diluted earnings per share (0.0041) 0.0015 (0.0026) 0.0034 0.0016 0.0050 For the six-month periods ended June 30, 2020 Consolidated financial statements Separate financial statements As previously reported Adjustment increase (decrease) As restated As previously reported Adjustment increase (decrease) As restated Loss on fair value measurement of financial assets - 8,805,624 8,805,624 - 8,805,624 8,805,624 Profit from operating activities 369,398,588 8,805,624 378,204,212 432,080,631 8,805,624 440,886,255 Profit before income tax expenses 250,224,650 (19,501,231) 230,723,419 323,799,701 (19,501,231) 304,298,470 189,467,231 8,805,624 198,272,855 374,383,107 8,805,624 383,188,731 Income tax expenses 37,533,625 (3,900,246) 33,633,379 8,716,132 (3,900,246) 4,815,886 41,955,069 1,761,125 43,716,194 8,801,361 1,761,125 10,562,486 Profit for the period 212,691,025 (15,600,985) 197,090,040 315,083,569 (15,600,985) 299,482,584 147,512,162 7,044,499 154,556,661 365,581,746 7,044,499 372,626,245 Loss on investment in equity designated at fair value through other comprehensive income (654,867,821) 19,501,231 (635,366,590323,276,057) (448,215,2388,805,624) 19,501,231 (428,714,007332,081,681) (101,986,577) (8,805,624) (110,792,201) Income tax relating to items that will not be reclassified 130,973,564 (3,900,246) 127,073,318 89,643,047 (3,900,246) 85,742,801 64,655,191 1,761,125 66,416,316 20,397,315 1,761,125 22,158,440 Other comprehensive income (loss) for the period, net of income tax (572,096,680) 15,600,985 (556,495,695289,805,789) (358,572,1917,044,499) 15,600,985 (342,971,206296,850,288) (81,589,262) (7,044,499) (88,633,761) Profit attributable - Owners of the parent 151,048,058 (15,600,985) 135,447,073 315,083,569 (15,600,985) 299,482,584 90,631,612 7,044,499 97,676,111 365,581,746 7,044,499 372,626,245 Basic earnings per share 0.0114 (0.0012) 0.0102 0.0238 (0.0012) 0.0226 0.0068 0.0006 0.0074 0.0276 0.0005 0.0281 Diluted earnings per share 0.0103 (0.0011) 0.0092 0.0214 (0.0010) 0.02040.0062 0.0004 0.0066 0.0249 0.0005 0.0254

BASIS FOR THE PREPARATION OF FINANCIAL STATEMENTS. 2.1 Basis for preparation of the interim financial statements These interim The financial statements are have been prepared in accordance with the accounting standards prescribed by Thai Accounts Act enunciated under the Accounting Standard No. 34 Interim Profession Act B.E.2547 by complying with Thai Financial Reporting, and the requirements of the Securities and Exchange Commission (SEC)Reporting Standards. The interim financial statements are intended to provide information additional to that included in the latest annual financial statements. Accordingly, they focus on new activities, events, and situations and not intended to re-emphasis on the information previously reported. The interim financial statements should therefore, be read in conjunction with presentation of the financial statements has been made in compliance with the Notification of the Department of Business Development, the Ministry of Commerce, re : the financial statements presentation for public limited company, issued under the year ended December 31, 2020Accounting Act B.E. 2543. The interim financial statements have been prepared on a historical cost basis except where otherwise disclosed in the accounting policies. The interim financial statements in Thai language are the official statutory financial statements of the Company. The interim financial statements in English language have been translated from the such financial statements in Thai language versionlanguage. 2.2 Basis for the preparation of consolidated financial statements 2.2.1 The consolidated financial statements have included the financial statements of Vibhavadi Medical Center Public Co., Ltd., subsidiaries and associated companies as follows; Type of Percentage of holding % of share capital Name of Company Type of business As at March 31, 2021 As at December 31, 2020 Head office location Chiang Mai Ram Medical Business Public Co., Ltd. Hospital 83.55 83.55 Chiang Mai Beauty Design Center Co., Ltd. Beauty Business 50.00 50.00 Bangkok V.precision Co., Ltd. Anti Aging Center 70.00 70.00 Bangkok Percentage of holding % of share capital Name of Company Type of business As at March 31, 2021 As at December 31, 2020 Head office location Vibharam Hospital Co., Ltd. Hospital 33.73 33.85 33.73 Bangkok Thippayabadin Co., Ltd. Trading medical 38.18 40.57 38.18 Bangkok instruments Bangpo General Hospital Co., Ltd. Hospital 28.57 28.57 Bangkok Chiang Mai Ram Hospital Co., Ltd. Hospital 47.09 47.09 Chiang Mai Hariphunchai Memorial Co., Ltd. Hospital 72.43 72.43 Lamphun Theppanya Business Co., Ltd. Hospital 47.09 47.09 Chiang Mai Ramkhamhaeng Chiangmai Hospital Co., Ltd. Ltd.* Hospital 45.14 45.14 45.53 45.53 Chiang Mai Khelang Nakorn Hospital Co., Ltd. Hospital 11.99 11.99 Lampang Pawo Hospital Co., Ltd. Hospital 23.54 23.54 TakTak * On February 24, 2020, Ramkhamhaeng Chiangmai Hospital Co., Ltd. had registered the capital increase for 56 million shares at Baht 10 per share, amounted Baht 560 million. Chiang Mai Ram Medical Business Public Company Limited had paid the share amounted Baht 40.32 million and from its subsidiary, Chiang Mai Ram Hospital Co., Ltd. amounted Baht 146.48 million totaled Baht 186.80 million, resulting in subsidiary - Chiang Mai Ram Hospital Co., Ltd. Held in that company to increase from 63.91% to 64.74% totaled of the group subsidiaries in held 82.74%. 2.2.2 Accounting policy for subsidiary companies will utilize the same policy as Vibhavadi Medical Center Public Company Limited. 2.2.3 Outstanding balances and significant transactions between the Company and its subsidiaries have been eliminated from the consolidated financial statements. 2.2.4 Non-controlling interests represent the portion of profit or loss and net assets of the subsidiaries that are not held by the Company and are presented separately from the portion of owners of the parent. 2.3 Financial reporting standards that became effective in the current period year During the periodyear, the Company and its subsidiaries have adopted the revised financial reporting standards and interpretations which are effective for fiscal years beginning on or after January 1, 2021. These financial reporting standards were aimed at alignment with the corresponding International Financial Reporting Standards with most of the changes directed towards clarifying accounting treatment and providing accounting guidance for users of the standards. The adoption of these financial reporting standards does not have any significant impact on the financial statements in the current periodyear. 2.4 Financial reporting standards that will become effective in the future The Federation of Accounting Professions has issued several revised TFRS 16 lease agreements financial reporting standards and has been published in the Government Gazette on January 27, 2021. There is added the requirements for the temporary exception arising from interest rate benchmark reformGazette, which an entity shall apply these amendments are effective for annual reporting periods fiscal years beginning on or after 1 January 12022. These financial reporting standards were aimed at alignment with the corresponding International Financial Reporting Standards with most of the changes directed towards clarifying accounting treatment and for some financial reporting standards, 2022 with earlier application permittedproviding temporary reliefs or temporary exemptions for users. The management of the Company and its subsidiaries are currently evaluating the have assessed that these revised standards will not have any significant impact of these standards to on the financial statements in the year when they are adopted. 2.5 Cumulative effect from the previous period's financial statements before classification and other financial asset value In 2020, the Company set an investment objective in the financial assets type investment in marketable equity with the nature held for sale as current financial assets. As a result, the Company has to reclassify and remeasure other financial assets by restating the financial statements for classification and measurement of such items into profit or loss to follow the objectives of the company. Therefore, the Company has restated the financial statements presented for comparative purposes and presented the consolidated statement of financial position and separate statement of financial position as at January 1, 2020 for comparative information as if the Company had correctly recorded the accounts. The cumulative effect of such adjustment is presented as a separate item in the statement of changes in shareholder's equity. The amounts of adjustments that have effect on the items in the statement of financial position and statement of comprehensive income are as follows: • Statements of financial position Consolidated financial statements As at December 31, 2020 As at January 1, 2020 As previously reported Adjustment increase (decrease) As restated As previously reported Adjustment increase (decrease) As restated Asset Other current financial asset - 156,910,000 156,910,000 - 56,102,150 56,102,150 Other non-current financial asset 7,900,167,417 (156,910,000) 7,743,257,417 7,360,434,110 (56,102,150) 7,304,331,960 Retained earnings - unappropriated 2,449,130,766 11,749,897 2,460,880,663 2,583,221,873 2,583,221,872 (3,923,2813,923,280) 2,579,298,592 Other components of shareholders' equity 1,496,407,944 (11,749,897) 1,484,658,047 1,377,393,221 3,923,281 1,381,316,502 3,923,280 1,381,316,501 Separate financial statements As at December 31, 2020 As at January 1, 2020 As previously reported Adjustment increase (decrease) As restated As previously reported Adjustment increase (decrease) As restated Asset Other current financial asset - 156,910,000 156,910,000 - 56,102,150 56,102,150 Other non-current financial asset 5,145,443,263 (156,910,000) 4,988,533,263 4,401,296,413 (56,102,150) 4,345,194,263 Retained earnings - unappropriated 980,203,060 11,749,897 991,952,957 1,022,620,856 (3,923,281) 1,018,697,575 Other components of shareholders' equity 738,042,960 (11,749,897) 726,293,063 490,009,847 3,923,281 493,933,128 • Statements of comprehensive income For the three-month periods year ended March period December 31, 2020 Consolidated financial statements Separate financial statements As previously reported Adjustment increase (decrease) As restated As previously reported Adjustment increase (decrease) As restated Loss on fair value measurement of financial assets - (19,501,231) (19,501,231) 19,591,473 19,591,473 - (19,501,231) (19,501,231) 19,591,473 19,591,473 Profit from operating activities 275,004,361 927,333,182 19,591,473 946,924,655 720,933,762 19,591,473 740,525,235 Profit (19,501,231) 255,503,130 353,967,286 (19,501,231) 334,466,055 Profit before loss)before income tax expenses 250,224,650 (19,501,231) 230,723,419 323,799,701 (19,501,231) 304,298,470 662,257,768 19,591,473 681,849,241 604,631,358 19,591,473 624,222,831 Income tax expenses 37,533,625 123,738,982 3,918,295 127,657,277 50,129,182 3,918,295 54,047,477 Profit (3,900,246loss) 33,633,379 8,716,132 (3,900,246) 4,815,886 Profit for the period 212,691,025 (15,600,985) 197,090,040 315,083,569 (15,600,985) 299,482,584 538,518,786 15,673,178 554,191,964 554,502,176 15,673,178 570,175,354 Loss on investment in equity designated at fair value through other comprehensive income 49,603,506 (654,867,82119,591,473) 19,501,231 30,012,033 310,041,393 (635,366,59019,591,473) (448,215,238) 19,501,231 (428,714,007) 290,449,920 Income tax relating to items that will not be reclassified 130,973,564 (3,900,2469,920,701) 127,073,318 89,643,047 3,918,295 (3,900,2466,002,406) 85,742,801 (62,008,280) 3,918,295 (58,089,985) Other comprehensive income (loss) for the period, net of income tax 36,299,591 (572,096,68015,673,178) 15,600,985 20,626,413 248,033,113 (556,495,69515,673,178) 232,359,935 Profit (358,572,191loss) 15,600,985 (342,971,206) Profit attributable - Owners of the parent 151,048,058 (15,600,985) 135,447,073 315,083,569 (15,600,985) 299,482,584 449,799,642 15,673,178 465,472,820 554,502,176 15,673,178 570,175,354 Basic earnings per share 0.0114 (0.0012) 0.0102 0.0238 (0.0012) 0.0226 0.0335 0.0012 0.0347 0.0413 0.0012 0.0425 Diluted earnings per share 0.0103 (0.0011) 0.0092 0.0214 (0.0010) 0.02040.0304 0.0011 0.0315 0.0375 0.0011 0.0386 3.1 Recognition of revenues Revenue from hospital operations which mainly consists of revenues for medical expenses, rental fee, medication fee and will be recognized when the service is provided to customers or medication has been delivered. Revenue for medical expenses in social security system has been recorded in accordance with rules, methods and conditions as specified units. Service revenue is recognized when service is provided to customers. Interest income is recognized over the period of time in consideration of the effective rate. Dividend income is recognized when the right to receive the dividend is established. Other revenues are recognized on accrual basis. 3.2 Recognition of expenses Expenses are recognized on an accrual basis. 3.3 Cash and cash equivalents Cash and cash equivalents consist of cash and deposits at financial institutions with an original maturity of 3 months or less and excluded cash at banks which are used for guarantee. 3.4 Trade and other receivables and allowance for doubtful accounts Trade receivables are stated at their invoice value less allowance for expected credit losses unless they contain significant financing components, when they are recognized at present value. The allowance for expected credit losses is disclosed in Note 3.7.

BASIS FOR THE PREPARATION OF FINANCIAL STATEMENTS. 2.1 Basis for preparation of the interim financial statements These interim financial statements are prepared in accordance with Thai Accounting Standard No. 34 (revised 2018) Interim Financial Reporting, and the requirements of the Securities and Exchange Commission (SEC). The interim financial statements are intended to provide information additional to that included in the latest annual financial statements. Accordingly, they focus on new activities, events, and situations and not intended to re-emphasis on the information previously reported. The interim financial statements should therefore, be read in conjunction with the financial statements for the year ended December 31, 20202018. The interim financial statements have been prepared on a historical cost basis except where otherwise disclosed in the accounting policies. The interim financial statements in Thai language are the official statutory financial statements of the Company. The interim financial statements in English language have been translated from the financial statements in Thai language version. 2.2 Basis for the preparation of consolidated interim financial statements 2.2.1 The consolidated interim financial statements have included the financial statements of Vibhavadi Medical Center Public Co., Ltd., subsidiaries and associated companies as follows; Percentage of holding % of share capital Name of Company Type of business company Direct subsidiary and associated companies As at March 31, 2021 September As at December 31, 2020 Head office location Princeton Park Suites Co., Ltd. Hotel 99.99 99.99 Bangkok Chiang Mai Ram Medical Business Public Co., Ltd. Hospital 83.55 83.55 Chiang Mai Beauty Design Center Co., Ltd. ** Beauty Business 50.00 50.00 - Bangkok V.precision Co., Ltd. Anti Aging Center 70.00 70.00 Bangkok Percentage of holding % of share capital Name of Company Type of business As at March 31, 2021 As at December Head office Name of company business 30, 2019 31, 2020 Head office 2018 location Associated company Vibharam Hospital Co., Ltd. Hospital 33.73 33.73 40.75 40.75 Bangkok Thippayabadin Co., Ltd. Trading medical 38.18 38.18 33.33 33.33 Bangkok instruments Bangpo General Hospital Co., Ltd. Hospital 28.57 28.57 Bangkok Indirect subsidiary and associated companies held by Chiang Mai Ram Medical Business Public Co., Ltd. Subsidiary company Chiang Mai Ram Hospital Co., Ltd. Hospital 47.09 47.09 Chiang Mai Hariphunchai Xxxxxx Xxx Xxxxxxxxxxxx Memorial Co., Ltd. Hospital 72.43 72.43 Lamphun held by Princeton Park Suites Co., Ltd. Subsidiary company Beauty Design Center Co., Ltd. ** Beauty Business - 50.00 Bangkok held by Chiang Mai Ram Hospital Co.,Ltd. Theppanya Business Co., Ltd. Hospital 47.09 47.09 Chiang Mai Ramkhamhaeng Chiangmai Hospital Co., Ltd. Ltd.* Hospital 45.14 45.14 - Chiang Mai ociated company Khelang Nakorn Hospital Co., Ltd. Hospital 11.99 11.99 Lampang Pawo Hospital Co., Ltd. Hospital 23.54 23.54 TakTak * According to the Board of Directors’ subsidiary Meeting No. 7/2018 dated December 25, 2018, it had the resolution for Chiang Mai Ram Medical Business Public Co., Ltd. and Chiang Mai Ram Hospital Co., Ltd. to invest in Ramkhamhaeng Chiangmai Hospital Co., Ltd. On March 1, 2019, its subsidiary had held the shares in such company for 18% and the indirect subsidiary - Chiang Mai Ram Hospital Co., Ltd. had held the shares for 63% totaled 81%. From investing and having control over such business, it had resulted for Xxxxxxxxxxxx Chiangmai Hospital Co., Ltd. to be considered as the subsidiary of Chiang Mai Ram Hospital Co., Ltd. The subsidiaries have adopted the financial statements of such companies to prepare the consolidated financial statements from the first quarter of 2019, onwards. On May 2, 2019, such company has call up Baht 7 per share, from its subsidiary - Chiang Mai Ram Medical Business Public Co., Ltd. had paid for the shares amounted Baht 50.40 million and from the indirect subsidiary - Chiang Mai Ram Hospital Co., Ltd. had paid for the shares amounted Baht 179.79 million totaled Baht 230.19 million, resulting in indirect subsidiary - Chiang Mai Ram Hospital Co., Ltd. held in that company to increase from 63.00% to 63.85% totaled 81.85%. And on July 26, 2019, such company has registered the capital increase for 4 million shares at Baht 10 per share, amounted Baht 40.00 million. Its subsidiary - Chiang Mai Ram Medical Business Public Co., Ltd. had paid the shares amounted Baht 7.20 million and from the indirect subsidiary, Chiang Mai Ram Hospital Co., Ltd. had paid the shares amounted Baht 25.82 million totaled Baht 33.02 million, resulting in the indirect subsidiary - Chiang Mai Ram Hospital Co., Ltd. held in such company to increase from 63.85% to 63.91% totaled 81.91%. ** According to the Board of Directors’ Extra Meeting No. 4/2019 dated September 25, 2019, it had the adjustment of investment structure to approved the Princeton Park Suites Co., Ltd. transfer all of shares of Beauty Design Center Co., Ltd., of shareholding 50 percent to be considered as the subsidiary and Legacy Golf (Thailand) Co., Ltd. of shareholding 10 percent to be considered as the other long-term investments to the company as discussed in Note 12 to the interim financial statements. 2.2.2 Accounting policy for subsidiary companies will utilize the same policy as Vibhavadi Medical Center Public Company Limited. 2.2.3 Outstanding balances and significant transactions between the Company and its subsidiaries have been eliminated from the consolidated financial statements. 2.2.4 Non-controlling interests represent the portion of profit or loss and net assets of the subsidiaries that are not held by the Company and are presented separately from the portion of owners of the parent. 2.3 Thai Financial reporting standards Reporting Standards that became become effective in the current period year During the period, the Company and its subsidiaries have adopted the revised and new financial reporting standards and interpretations (revised 2018) including new accounting treatment guidance, which are effective for fiscal years beginning on or after January 1, 20212019. These financial reporting standards were aimed at alignment with the corresponding International Financial Reporting Standards with most of the changes and clarifications directed towards clarifying accounting treatment and providing accounting guidance for users of disclosures in the standardsnotes to financial statements. The adoption of these financial reporting standards does not have any significant impact on the financial statements in the current period. 2.4 Financial reporting standards that will become effective in the future The Federation of Accounting Professions has revised TFRS 16 lease agreements and published in the Government Gazette on January 27, 2021. There is added the requirements for the temporary exception arising from interest rate benchmark reform, which an entity shall apply these amendments for annual reporting periods beginning on or after January 1, 2022 with earlier application permitted. The management of the Company and its subsidiaries are currently evaluating the impact of these standards to the subsidiaries’ financial statements in the year when they are adopted. 2.5 Cumulative effect from the previous period's financial statements before classification and other financial asset value In 2020statements. However, the Company set an investment objective in the financial assets type investment in marketable equity with the nature held for sale new standard involves changes to key principles, as current financial assets. As a result, the Company has to reclassify and remeasure other financial assets by restating the financial statements for classification and measurement of such items into profit or loss to follow the objectives of the company. Therefore, the Company has restated the financial statements presented for comparative purposes and presented the consolidated statement of financial position and separate statement of financial position as at January 1, 2020 for comparative information as if the Company had correctly recorded the accounts. The cumulative effect of such adjustment is presented as a separate item in the statement of changes in shareholder's equity. The amounts of adjustments that have effect on the items in the statement of financial position and statement of comprehensive income are as follows: • Statements of financial position Consolidated financial statements As at December 31, 2020 As at January 1, 2020 As previously reported Adjustment increase (decrease) As restated As previously reported Adjustment increase (decrease) As restated Asset Other current financial asset - 156,910,000 156,910,000 - 56,102,150 56,102,150 Other non-current financial asset 7,900,167,417 (156,910,000) 7,743,257,417 7,360,434,110 (56,102,150) 7,304,331,960 Retained earnings - unappropriated 2,449,130,766 11,749,897 2,460,880,663 2,583,221,873 (3,923,281) 2,579,298,592 Other components of shareholders' equity 1,496,407,944 (11,749,897) 1,484,658,047 1,377,393,221 3,923,281 1,381,316,502 Separate financial statements As at December 31, 2020 As at January 1, 2020 As previously reported Adjustment increase (decrease) As restated As previously reported Adjustment increase (decrease) As restated Asset Other current financial asset - 156,910,000 156,910,000 - 56,102,150 56,102,150 Other non-current financial asset 5,145,443,263 (156,910,000) 4,988,533,263 4,401,296,413 (56,102,150) 4,345,194,263 Retained earnings - unappropriated 980,203,060 11,749,897 991,952,957 1,022,620,856 (3,923,281) 1,018,697,575 Other components of shareholders' equity 738,042,960 (11,749,897) 726,293,063 490,009,847 3,923,281 493,933,128 • Statements of comprehensive income For the three-month periods ended March 31, 2020 Consolidated financial statements Separate financial statements As previously reported Adjustment increase (decrease) As restated As previously reported Adjustment increase (decrease) As restated Loss on fair value measurement of financial assets - (19,501,231) (19,501,231) - (19,501,231) (19,501,231) Profit from operating activities 275,004,361 (19,501,231) 255,503,130 353,967,286 (19,501,231) 334,466,055 Profit before income tax expenses 250,224,650 (19,501,231) 230,723,419 323,799,701 (19,501,231) 304,298,470 Income tax expenses 37,533,625 (3,900,246) 33,633,379 8,716,132 (3,900,246) 4,815,886 Profit for the period 212,691,025 (15,600,985) 197,090,040 315,083,569 (15,600,985) 299,482,584 Loss on investment in equity designated at fair value through other comprehensive income (654,867,821) 19,501,231 (635,366,590) (448,215,238) 19,501,231 (428,714,007) Income tax relating to items that will not be reclassified 130,973,564 (3,900,246) 127,073,318 89,643,047 (3,900,246) 85,742,801 Other comprehensive income (loss) for the period, net of income tax (572,096,680) 15,600,985 (556,495,695) (358,572,191) 15,600,985 (342,971,206) Profit attributable - Owners of the parent 151,048,058 (15,600,985) 135,447,073 315,083,569 (15,600,985) 299,482,584 Basic earnings per share 0.0114 (0.0012) 0.0102 0.0238 (0.0012) 0.0226 Diluted earnings per share 0.0103 (0.0011) 0.0092 0.0214 (0.0010) 0.0204summarized below.

BASIS FOR THE PREPARATION OF FINANCIAL STATEMENTS. 2.1 Basis for preparation of the interim financial statements These interim financial statements are prepared in accordance with Thai Accounting Standard No. 34 Interim Financial Reporting, and the requirements of the Securities and Exchange Commission (SEC). The interim financial statements are intended to provide information additional to that included in the latest annual financial statements. Accordingly, they focus on new activities, events, and situations and not intended to re-emphasis on the information previously reported. The interim financial statements should therefore, be read in conjunction with the financial statements for the year ended December 31, 2020. The interim financial statements have been prepared on a historical cost basis except where otherwise disclosed in the accounting policies. The interim financial statements in Thai language are the official statutory financial statements of the Company. The interim financial statements in English language have been translated from the financial statements in Thai language version. 2.2 Basis for the preparation of consolidated financial statements 2.2.1 The consolidated financial statements have included the financial statements of Vibhavadi Medical Center Public Co., Ltd., subsidiaries and associated companies as follows; Percentage of holding % of share capital Name of Company Type of business As at March 31September 30, 2021 As at December 31, 2020 Head office location Chiang Mai Ram Medical Business Public Co., Ltd. Hospital 83.55 83.55 Chiang Mai Beauty Design Center Co., Ltd. Beauty Business 50.00 50.00 Bangkok V.precision Co., Ltd. Anti Aging Center 70.00 70.00 Bangkok Percentage of holding % of share capital Name of Company Type of business As at March 31, 2021 As at December 31, 2020 Head office location Vibharam Hospital Co., Ltd. Hospital 33.73 33.73 Bangkok Thippayabadin Co., Ltd. Trading medical 38.18 38.18 Bangkok instruments Bangpo General Hospital Co., Ltd. Hospital 28.57 28.57 Bangkok Chiang Mai Ram Hospital Co., Ltd. Hospital 47.09 47.09 Chiang Mai Hariphunchai Memorial Co., Ltd. Hospital 72.43 72.43 Lamphun Theppanya Business Co., Ltd. Hospital 47.09 47.09 Chiang Mai Ramkhamhaeng Chiangmai Hospital Co., Ltd. Hospital 45.14 45.14 Chiang Mai Khelang Nakorn Hospital Co., Ltd. Hospital 11.99 11.99 Lampang Pawo Hospital Co., Ltd. Hospital 23.54 23.54 Tak 2.2.2 Accounting policy for subsidiary companies will utilize the same policy as Vibhavadi Medical Center Public Company Limited. 2.2.3 Outstanding balances and significant transactions between the Company and its subsidiaries have been eliminated from the consolidated financial statements. 2.2.4 Non-controlling interests represent the portion of profit or loss and net assets of the subsidiaries that are not held by the Company and are presented separately from the portion of owners of the parent. 2.3 Financial reporting standards that became effective in the current period During the period, the Company and its subsidiaries have adopted the revised financial reporting standards and interpretations which are effective for fiscal years beginning on or after January 1, 2021. These financial reporting standards were aimed at alignment with the corresponding International Financial Reporting Standards with most of the changes directed towards clarifying accounting treatment and providing accounting guidance for users of the standards. However, COVID-19 Related Rent Concessions beyond June 30, 2021 were adjusted in the financial reporting standard No.16 lease effective from April 1, 2021. Therefore, it is permitted for the company to adopt before the effective date. Such adjustment is a relief of practice, the lessee does not necessarily have to assess that the consent to reduce the rent is a change of lease agreement or not. The consent to reduce the rent is a direct result of the Coronavirus 2019 pandemic (COVID-19) and that falls under the condition specified (revised paragraph 46 khor.2 from formerly June 30, 2021 to June 30, 2022). The recording of the consent to reduce the rent is as if “not a change of the lease”, which during the period, the Federation of Accounting Professions has issued and published in the Government Gazette. The adoption of these financial reporting standards does not have any significant impact on the financial statements in the current period. 2.4 Financial reporting standards that will become effective in the future The Federation of Accounting Professions has issued several revised TFRS 16 lease agreements financial reporting standards and has been published in the Government Gazette on January 27, 2021. There is added the requirements for the temporary exception arising from interest rate benchmark reformGazette, which an entity shall apply these amendments are effective for annual reporting periods fiscal years beginning on or after 1 January 12022. These financial reporting standards were aimed at alignment with the corresponding International Financial Reporting Standards with most of the changes directed towards clarifying accounting treatment and for some financial reporting standards, 2022 with earlier application permittedproviding temporary reliefs or temporary exemptions for users. The management of the Company and its subsidiaries are currently evaluating the impact of these standards to the financial statements in the year when they are adopted. 2.5 Cumulative effect from the previous period's financial statements before classification and other financial asset value In 2020, the Company set an investment objective in the financial assets type investment in marketable equity with the nature held for sale as current financial assets. As a result, the Company has to reclassify and remeasure other financial assets by restating the financial statements for classification and measurement of such items into profit or loss to follow the objectives of the company. Therefore, the Company has restated the financial statements presented for comparative purposes and presented the consolidated statement of financial position and separate statement of financial position as at January 1, 2020 for comparative information as if the Company had correctly recorded the accounts. The cumulative effect of such adjustment is presented as a separate item in the statement of changes in shareholder's equity. The amounts of adjustments that have effect on the items in the statement of financial position and statement of comprehensive income are as follows: • Statements of financial position Consolidated financial statements As at December 31, 2020 As at January 1, 2020 As previously reported Adjustment increase (decrease) As restated As previously reported Adjustment increase (decrease) As restated Asset Other current financial asset - 156,910,000 156,910,000 - 56,102,150 56,102,150 Other non-current financial asset 7,900,167,417 (156,910,000) 7,743,257,417 7,360,434,110 (56,102,150) 7,304,331,960 Retained earnings - unappropriated 2,449,130,766 11,749,897 2,460,880,663 2,583,221,873 (3,923,281) 2,579,298,592 Other components of shareholders' equity 1,496,407,944 (11,749,897) 1,484,658,047 1,377,393,221 3,923,281 1,381,316,502 Separate financial statements As at December 31, 2020 As at January 1, 2020 As previously reported Adjustment increase (decrease) As restated As previously reported Adjustment increase (decrease) As restated Asset Other current financial asset - 156,910,000 156,910,000 - 56,102,150 56,102,150 Other non-current financial asset 5,145,443,263 (156,910,000) 4,988,533,263 4,401,296,413 (56,102,150) 4,345,194,263 Retained earnings - unappropriated 980,203,060 11,749,897 991,952,957 1,022,620,856 (3,923,281) 1,018,697,575 Other components of shareholders' equity 738,042,960 (11,749,897) 726,293,063 490,009,847 3,923,281 493,933,128 • Statements of comprehensive income For the three-month periods ended March 31September 30, 2020 Consolidated financial statements Separate financial statements As previously reported Adjustment increase (decrease) As restated As previously reported Adjustment increase (decrease) As restated Loss on fair value measurement of financial assets - (19,501,231) (19,501,231) 23,486,054 23,486,054 - (19,501,231) (19,501,231) 23,486,054 23,486,054 Profit from operating activities 275,004,361 261,889,273 23,486,054 285,375,327 162,612,505 23,486,054 186,098,559 Profit (19,501,231loss)before income tax expenses 96,571,179 23,486,054 120,057,233 133,318,884 23,486,054 156,804,938 Income tax expenses 43,367,648 4,697,210 48,064,858 17,854,892 4,697,210 22,552,102 Profit (loss) 255,503,130 353,967,286 for the period 53,203,531 18,788,844 71,992,375 115,463,992 18,788,844 134,252,836 Loss on investment in equity designated at fair value through other comprehensive income 194,134,499 (19,501,23123,486,054) 334,466,055 170,648,445 256,176,773 (23,486,054) 232,690,719 Income tax relating to items that will not be reclassified (38,826,879) 4,697,210 (34,129,669) (51,235,354) 4,697,210 (46,538,144) Other comprehensive income (loss) for the period, net of income tax 165,400,433 (18,788,844) 146,611,589 204,941,419 (18,788,844) 186,152,575 Profit (loss) attributable - Owners of the parent 36,478,885 18,788,844 55,267,729 115,463,992 18,788,844 134,252,836 Basic earnings per share 0.0027 0.0014 0.0041 0.0085 0.0014 0.0099 Diluted earnings per share 0.0025 0.0012 0.0037 0.0078 0.0012 0.0090 For the nine-month periods ended September 30, 2020 Consolidated financial statements Separate financial statements As previously reported Adjustment increase (decrease) As restated As previously reported Adjustment increase (decrease) As restated Loss on fair value measurement of financial assets - 32,291,678 32,291,678 - 32,291,678 32,291,678 Profit from operating activities 631,287,861 32,291,678 663,579,539 594,693,136 32,291,678 626,984,814 Profit before income tax expenses 250,224,650 (19,501,231) 230,723,419 323,799,701 (19,501,231) 304,298,470 286,038,410 32,291,678 318,330,088 507,701,991 32,291,678 539,993,669 Income tax expenses 37,533,625 (3,900,246) 33,633,379 8,716,132 (3,900,246) 4,815,886 85,322,717 6,458,335 91,781,052 26,656,253 6,458,335 33,114,588 Profit for the period 212,691,025 (15,600,985) 197,090,040 315,083,569 (15,600,985) 299,482,584 200,715,693 25,833,343 226,549,036 481,045,738 25,833,343 506,879,081 Loss on investment in equity designated at fair value through other comprehensive income (654,867,821) 19,501,231 (635,366,590129,141,558) (448,215,23832,291,678) 19,501,231 (428,714,007161,433,236) 154,190,196 (32,291,678) 121,898,518 Income tax relating to items that will not be reclassified 130,973,564 25,828,312 6,458,335 32,286,647 (3,900,24630,838,039) 127,073,318 89,643,047 6,458,335 (3,900,24624,379,704) 85,742,801 Other comprehensive income (loss) for the period, net of income tax (572,096,680) 15,600,985 (556,495,695124,405,356) (358,572,19125,833,343) 15,600,985 (342,971,206150,238,699) 123,352,157 (25,833,343) 97,518,814 Profit attributable - Owners of the parent 151,048,058 (15,600,985) 135,447,073 315,083,569 (15,600,985) 299,482,584 127,110,497 25,833,343 152,943,840 481,045,738 25,833,343 506,879,081 Basic earnings per share 0.0095 0.0019 0.0114 (0.0012) 0.0102 0.0238 (0.0012) 0.0226 0.0360 0.0019 0.0379 Diluted earnings per share 0.0103 (0.0011) 0.0092 0.0214 (0.0010) 0.02040.0086 0.0018 0.0104 0.0326 0.0018 0.0344

BASIS FOR THE PREPARATION OF FINANCIAL STATEMENTS. 2.1 Basis for preparation of the interim financial statements These interim financial statements are prepared in accordance with Thai Accounting Standard No. 34 Interim Financial Reporting, and the requirements of the Securities and Exchange Commission (SEC). The interim financial statements are intended to provide information additional to that included in the latest annual financial statements. Accordingly, they focus on new activities, events, and situations and not intended to re-emphasis on the information previously reported. The interim financial statements should therefore, be read in conjunction with the financial statements for the year ended December 31, 20202022. The interim financial statements have been prepared on a historical cost basis except where otherwise disclosed in the accounting policies. The interim financial statements in Thai language are the official statutory financial statements of the Company. The interim financial statements in English language have been translated from the financial statements in Thai language version. 2.2 Basis for the preparation of consolidated financial statements 2.2.1 The consolidated financial statements have included the financial statements of Vibhavadi Medical Center Public Co., Ltd., subsidiaries and associated companies as follows; Percentage of holding % of share capital Name of Company Type of business As at March 31, 2021 2023 As at December 31, 2020 2022 Head office location Chiang Mai Ram Medical Business Public Co., Ltd. Hospital 83.55 83.55 Chiang Mai Beauty Design Center Co., Ltd. Beauty Business 50.00 50.00 46.50 49.72 Bangkok V.precision V precision Co., Ltd. Anti Aging Center 70.00 70.00 Bangkok Percentage of holding % of share capital Name of Company Type of business As at March 31, 2021 2023 As at December 31, 2020 2022 Head office location Vibharam Hospital Co., Ltd. Hospital 33.73 33.73 33.85 33.85 Bangkok Thippayabadin Co., Ltd. Trading medical 38.18 38.18 36.50 36.50 Bangkok instruments Bangpo General Hospital Co., Ltd. Hospital 28.57 28.57 Bangkok Chiang Mai Ram Hospital Co., Ltd. Hospital 47.09 47.09 Chiang Mai Hariphunchai Memorial Co., Ltd. Hospital 72.43 72.43 Lamphun Theppanya Business Co., Ltd. Hospital 47.09 47.09 Chiang Mai Ramkhamhaeng Chiangmai Hospital Co., Ltd. Hospital 45.14 45.14 45.53 45.53 Chiang Mai (and held by Chiang Mai Ram Medical Business Public Co., Ltd. 18%) Pawo Hospital Co., Ltd. Hospital 28.00 28.00 Tak Medica Bangkok Clinic Co., Ltd. (and held by Beauty Design Center Co., Ltd. 30.00%) Specialized Disease Clinic 34.95 36.00 Bangkok Khelang Nakorn Hospital Co., Ltd. Hospital 11.99 11.99 Lampang Pawo Watcharasirivej Co.,Ltd. Hospital 21.47 21.47 Chiang rai (and held by Chiang Mai Ram Hospital Co., Ltd. Hospital 23.54 23.54 Tak3.33%, Chiang Mai Ram Medical Business Public Co., Ltd. 1.67% and Theppanya Business Co., Ltd. 0.83%) 2.2.2 The Company is deemed to have control over an investee or subsidiaries if it has rights, or is exposed, to variable returns from its involvement with the investee, and it has the ability to direct the activities that affect the amount of its returns. 2.2.3 Subsidiaries are fully consolidated, being the date on which the Company obtains control, and continue to be consolidated until the date when such control ceases. 2.2.4 The accounting period of the investments of subsidiary companies are ended at the same period of Vibhavadi Medical Center Public Co., Ltd. The percentage of shareholding at 99.99% of the subsidiary companies, the Company is treated as holding of 100% of consolidated financial statements and recorded under the cost method. 2.2.5 Accounting policy for subsidiary companies will utilize the same policy as Vibhavadi Medical Center Public Company Limited.Co., Ltd. 2.2.3 2.2.6 Outstanding balances and significant transactions between the Company and its subsidiaries have been eliminated from the consolidated financial statements. 2.2.4 2.2.7 Non-controlling interests represent the portion of profit or loss and net assets of the subsidiaries that are not held by the Company and are presented separately from the portion of owners of the parent. 2.3 Financial reporting standards that became effective in the current period During the period, the Company and its subsidiaries have Group has adopted the revised financial reporting standards and interpretations standards, which are effective for fiscal years beginning on or after January 1, 20212023. These This revision is for the financial reporting standards were aimed at alignment to be clearer and more appropriate and to conform with international financial reporting standards. Such revision does not affect the corresponding International Financial Reporting Standards with most principles of the changes directed towards clarifying accounting treatment standards and providing accounting guidance for does not affect the users of the financial reporting standards. The adoption of these financial reporting standards does not have any significant impact on the financial statements in the current period. 2.4 Financial reporting standards that will become effective in the future The Federation of Accounting Professions has revised TFRS 16 lease agreements and published in the Government Gazette on January 27, 2021. There is added the requirements for the temporary exception arising from interest rate benchmark reform, which an entity shall apply these amendments for annual reporting periods beginning on or after January 1, 2022 with earlier application permitted. The management of the Company and its subsidiaries are currently evaluating the impact of these standards to the financial statements in the year when they are adopted. 2.5 Cumulative effect from the previous period's financial statements before classification and other financial asset value In 2020, the Company set an investment objective in the financial assets type investment in marketable equity with the nature held for sale as current financial assets. As a result, the Company has to reclassify and remeasure other financial assets by restating the financial statements for classification and measurement of such items into profit or loss to follow the objectives of the company. Therefore, the Company has restated the financial statements presented for comparative purposes and presented the consolidated statement of financial position and separate statement of financial position as at January 1, 2020 for comparative information as if the Company had correctly recorded the accounts. The cumulative effect of such adjustment is presented as a separate item in the statement of changes in shareholder's equity. The amounts of adjustments that have effect on the items in the statement of financial position and statement of comprehensive income are as follows: • Statements of financial position Consolidated financial statements As at December 31, 2020 As at January 1, 2020 As previously reported Adjustment increase (decrease) As restated As previously reported Adjustment increase (decrease) As restated Asset Other current financial asset - 156,910,000 156,910,000 - 56,102,150 56,102,150 Other non-current financial asset 7,900,167,417 (156,910,000) 7,743,257,417 7,360,434,110 (56,102,150) 7,304,331,960 Retained earnings - unappropriated 2,449,130,766 11,749,897 2,460,880,663 2,583,221,873 (3,923,281) 2,579,298,592 Other components of shareholders' equity 1,496,407,944 (11,749,897) 1,484,658,047 1,377,393,221 3,923,281 1,381,316,502 Separate financial statements As at December 31, 2020 As at January 1, 2020 As previously reported Adjustment increase (decrease) As restated As previously reported Adjustment increase (decrease) As restated Asset Other current financial asset - 156,910,000 156,910,000 - 56,102,150 56,102,150 Other non-current financial asset 5,145,443,263 (156,910,000) 4,988,533,263 4,401,296,413 (56,102,150) 4,345,194,263 Retained earnings - unappropriated 980,203,060 11,749,897 991,952,957 1,022,620,856 (3,923,281) 1,018,697,575 Other components of shareholders' equity 738,042,960 (11,749,897) 726,293,063 490,009,847 3,923,281 493,933,128 • Statements of comprehensive income For the three-month periods ended March 31, 2020 Consolidated financial statements Separate financial statements As previously reported Adjustment increase (decrease) As restated As previously reported Adjustment increase (decrease) As restated Loss on fair value measurement of financial assets - (19,501,231) (19,501,231) - (19,501,231) (19,501,231) Profit from operating activities 275,004,361 (19,501,231) 255,503,130 353,967,286 (19,501,231) 334,466,055 Profit before income tax expenses 250,224,650 (19,501,231) 230,723,419 323,799,701 (19,501,231) 304,298,470 Income tax expenses 37,533,625 (3,900,246) 33,633,379 8,716,132 (3,900,246) 4,815,886 Profit for the period 212,691,025 (15,600,985) 197,090,040 315,083,569 (15,600,985) 299,482,584 Loss on investment in equity designated at fair value through other comprehensive income (654,867,821) 19,501,231 (635,366,590) (448,215,238) 19,501,231 (428,714,007) Income tax relating to items that will not be reclassified 130,973,564 (3,900,246) 127,073,318 89,643,047 (3,900,246) 85,742,801 Other comprehensive income (loss) for the period, net of income tax (572,096,680) 15,600,985 (556,495,695) (358,572,191) 15,600,985 (342,971,206) Profit attributable - Owners of the parent 151,048,058 (15,600,985) 135,447,073 315,083,569 (15,600,985) 299,482,584 Basic earnings per share 0.0114 (0.0012) 0.0102 0.0238 (0.0012) 0.0226 Diluted earnings per share 0.0103 (0.0011) 0.0092 0.0214 (0.0010) 0.0204